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ABSTRACT
Pattern of presentation and management of acute ST-segment elevation 
myocardial infarction (STEMI) to a tertiary care centre in a district capital 
in South India
Background:  Cardiovascular disease (CVD) is the leading cause of death worldwide and by 
2010, 60% of world’s heart disease is expected to occur in India. The prevalence of diabetes 
and obesity has increased. Rates of primary percutaneous coronary intervention (PCI) have 
increased in western population.  Mortality rates from STEMI are declining worldwide.  We 
sought to study the pattern of presentation and management of patients presenting with acute 
STEMI to a tertiary care centre in a district capital in South India.
Methods:  150 consecutive patients presenting with acute STEMI to a tertiary care centre 
were enrolled. The demographic, socioeconomic, risk factor, clinical and laboratory profile of 
patients presenting with STEMI were recorded. The reperfusion strategy, use of guideline 
based  acute  medical  therapy,  in-hospital  and 30  day outcomes were  recorded  for  these 
patients.
Results: The mean age of study population was 57 ± 12 years. There were 117(78%) males 
and 33(22%) females.   84(56%) belonged to  the middle class, 20(13.3%) and 46(30.7%) 
belonged to the upper and lower socioeconomic class respectively. The median pre-hospital 
delay was 4 hours. The median door-to-needle time was 45 minutes. The median door-to-
balloon time was 92 minutes.  73(48.7%) had diabetes, 64(42.7%) had hypertension, 51(34%) 
were smokers. The mean body mass index was 23.9 ± 2.8.  The mean ejection fraction was 
45 ± 9%. 76(50.7%) had anterior wall myocardial infarction and 68(45.3%) had inferior wall 
myocardial infarction. 130 (86.7%) underwent thrombolysis and 11(7.3%) underwent primary 
PCI.  Streptokinase was the thrombolytic agent used in 124(95.4%) and tenecteplase in the 
rest.  89(59.3%) had >50% ST segment resolution post reperfusion. 28(18.7%) underwent 
coronary angiography during index hospitalization. Acute pharmacotherapy was widely used: 
Aspirin  (98.7%),  clopidogrel  (97.3%),  beta-blocker  (88%),  Angiotensin  converting  enzyme 
inhibitors (ACEI) (88.7%) and statins (94%).  The in-hospital outcomes were death (12%), re-
infarction (0.7%), recurrent angina (8%), arrhythmia (7.3%), LV systolic dysfunction (60.7%), 
stroke (1.3%), cardiogenic shock (3.3%), rescue PCI (5.3%), adjunct PCI (2.7%). The mean 
duration of hospital stay was 2.6 ± 2 days. The 30 day outcomes were death (0.7%0, re-
infarction (2.7%0, recurrent angina (12%), and heart failure (11.3%).
Conclusion:   Patients  presenting  with  STEMI  are  younger  in  comparison  to  western 
population.  The proportion  of  women presenting  with  STEMI  and prevalence of  diabetes 
mellitus has increased. Women have significantly higher prevalence of diabetes than men. 
The pre-hospital delay is longer than Western population. Thrombolysis is the most commonly 
used reperfusion therapy.  In-hospital mortality rates are declining but still  higher than the 
western  population.  Use  of  guideline  based  prescription  of   acute  medical  therapy  has 
increased.
INTRODUCTION
Cardiovascular  disease (CVD) is  the leading cause of  death worldwide and has reached 
epidemic  proportions.   The  prevalence  of  CVD  shows  remarkable  geographic  variation. 
Mortality associated with CVD is declining in Western Europe and North America1 , but the 
burden of CVD in developing countries continues to rise and is expected to be the major 
cause of death in adults from low and middle income countries worldwide2 . Moreover South 
Asians have a greater prevalence of coronary risk factors than the rest of the world, and 
coronary artery disease (CAD) often manifests at an early age which creates pressure on 
society and the economy 3 . 
Over the last decade, western countries have shown decrease in mortality due to ST-segment 
elevation myocardial infarction (STEMI).  More women and elderly are presenting with STEMI 
4.  Among the risk factors, there has been significant increase in incidence of diabetes and 
obesity 5.   There  were  marked  geographic  differences  in  extent  of  pre-hospital  delay  in 
patients with STEMI 6.  More number of people are treated by primary percutaneous coronary 
intervention (PCI) compared to thrombolytic therapy 7.  
 Major  risk  factors  are  the  same  around  the  world.   Tobacco  use,  dyslipidemia  and 
hypertension are the main determinants of population attributable risk (PAR) worldwide. As 
the Indian economy grows there is a possibility for further increase in cardiovascular disease. 
The  prevalence  of  overweight  and  obesity  is  increasing,  and  more  importantly,  rates  of 
diabetes are increasing even more rapidly.  A moderate increase in body mass index makes 
south Asians more prone for insulin resistance and related diseases 8 . 
Earlier studies done in India and study done in this same institution have shown significantly 
prolonged pre-hospital delay. Studies done in Indian population have shown that the patients 
presenting  with  acute  coronary syndrome are  younger  and they present  more  often  with 
STEMI as compared to that of developed countries9 .   Moreover the use of lipid lowering 
therapies, beta blockers and angiotensin converting enzyme inhibitors (ACEI) were lower. 
Fewer patients had an invasive approach with coronary revascularization.  Especially, in poor 
people,  substantial  underutilization  of  evidence  –  based  treatments  were  seen.   Indian 
hospitals have access to the most modern technologies on par with the rest of the world. 
They can provide the latest and the best medical care as long as the patient can afford it. 
But,  focus  on  advanced  technology can  interrupt  delivery  of  inexpensive  drugs  that  can 
reduce mortality and morbidity in acute coronary syndromes.  In fact widespread use of these 
drugs in the hospital and at discharge from hospital has been the major cause of improved 
outcomes in acute coronary syndromes in developed countries 10 .   It has been shown that 
initiatives  to  enhance  quality  through  consistent  delivery  of  these  therapies  can  achieve 
remarkable  improvements  in  survival11 .   The  strategies  to  improve  outcomes  of  acute 
coronary syndrome are not expensive.  Most of the decline in USA is believed to be due to 
secondary to improving risk factor profiles, effective primary and secondary treatment of acute 
coronary  syndrome  with  beta  blockers,  statins,  aspirin  and  ACEI.   In  fact,  expensive 
intervention such as revascularization accounts only for 5% of this benefit 12
This study was done to assess the pattern of presentation and management of patients with 
acute STEMI to a tertiary care centre in a district capital in South India in the current era.  It 
would  also  evaluate  the  extent  of  pre-hospital  delay  in  seeking  medical  care  in  patients 
presenting to a tertiary care centre with acute STEMI.  It would also be informative to know of 
any change in risk factor profile of patients presenting with STEMI in the current era. This 
would also assess the type of the reperfusion strategy used and assess appropriate use of 
pharmacotherapy as per current guidelines.  The in-hospital and 30 day outcomes also need 
to be assessed in the present era due to greater advancements in the treatment of acute 
myocardial  infarction  (AMI),  better  knowledge  of  the  pathology  and  complications  of 




The  aim  is  to  study  the  pattern  and  presentation  of  ST-segment  Elevation  Myocardial 
Infarction to a tertiary care centre in a district capital in South India
OBJECTIVES:
1. To  study  the  demographic,  socioeconomic,  risk  factor  and  clinical  profile  of  patients 
presenting with acute ST-segment elevation myocardial infarction.
2. To  study the  time  delay associated  with  presentation  and  management  of  acute  ST- 
segment elevation myocardial infarction.
3. To study the in-hospital outcomes in patients presenting with acute ST-segment elevation 
myocardial infarction.
4. To study the 30 day outcomes in patients presenting with acute ST-segment elevation 
myocardial infarction.
5. To compare and contrast the patient characteristics,  presentation and management of 
acute ST-segment elevation myocardial infarction with that of data obtained from  1999 – 
2003 in the same institution.
REVIEW OF LITERATURE
Global and regional burden of cardiovascular disease 
 CVD has become the leading cause of death and loss of disability adjusted life years in many 
developing countries and will  soon attain that status in several others 13 .   The projected 
increase in the proportion of all deaths that are due to cardiovascular causes, from about 25 
percent in 1990 to more than 40 percent in 2020, signals the advance of the epidemic of 
CVD.  Coronary heart disease (CHD) is the leading cause of death in adults in the United 
States, accounting for about one-third of all deaths in subjects over age of 35 13 .  The death 
rate is higher in men than in women (three times higher at ages 25 to 34, falling to 1.6 times 
at ages 75 to 84) and in blacks compared to whites, an excess that disappears by age 75.
Although  age-adjusted  cardiovascular  death  rates  have  declined  in  several  developed 
countries in past decades, rates of CVD have risen greatly in low-income and middle-income 
countries.  The fact that 80% of deaths from CVD worldwide and 87% of related disability 
currently occur in low-income and middle income countries indicates the magnitude of the 
problem14 . The Indian subcontinent is home to 20 per cent of the world’s population and may 
be one of the regions with the highest burden of CVD in the world.  The high burden of 
mortality from cardiovascular causes in developing countries is estimated to increase to 19 
million by 2020  15 .    This  is  only partially explained by their  large population.   In  India, 
ischemic heart disease may not be largely explained by traditional risk factors 16 .
Over the past 40 years, the prevalence of CHD in urban India has increased by a factor of six 
to eight, to about 10 percent among persons 35 to 64 years of age.  Coronary deaths in India 
are expected to reach 2 million by 2010.  At the turn of the century, it was reported that CHD 
mortality was expected to increase approximately 29 percent in women and 48 percent in 
men  in  developed  countries  between  1990  and  2020.   The  corresponding  estimated 
increases in developing countries were 120 percent in women and 137 percent in men 17 .
In non-Western countries, deaths due to CVD tend to occur a decade or two earlier than they 
do in Western countries; nearly half occur before 70 years of age, whereas only one fifth 
occur  so  early  in  the  West  — a  difference attributable  to  both  the  earlier  occurrence of 
cardiovascular events and the lower level of clinical care available 18 .  As a result, the Indian 
subcontinent suffers from a tremendous loss of productive working years due to CVD deaths: 
an estimated 9.2 million productive years of life were lost in India in 2000, with an expected 
increase to 17.9 million years in 2030 (almost ten times the projected loss of productive life in 
the United States) 19 .
Of the 24 million people expected to die of CVD in 2020, about 9.3 million will be between 30 
and 69 years of age.  Most of them will be in non-Western countries.  A huge increase in the 
prevalence of diabetes will further increase the burden of CVD.  India also has the highest 
number of diabetics in the world20 .  India, where nearly 20 million people had diabetes in 
1995, will see atleast a tripling of that number by 2025.
The  huge  burden  of  CVD  in  the  Indian  subcontinent  is  the  consequence  of  the  large 
population and the high prevalence of CVD risk factors.  Moreover, the projected increase in 
deaths and disability from CVD is expected to follow closely an explosion in the prevalence of 
traditional risk factors.  Driving this steep rise in CVD risk factor burden is the rapid increase 
in  the  proportion  of  urban  inhabitants  (currently  at  30% with  a  projected  rise  to  43% in 
2021)21 .  Urbanization is characterized by a marked increase in the intake of energy-dense 
foods, a decrease in physical activity, and a heightened level of psychosocial stress, all of 
which promote the development of diabetes, hypertension, and dyslipidemia17 .
Risk factors and cardiovascular disease
A risk factor can be defined as a characteristic that is associated with increased or decreased 
likelihood of subsequent development of CVD.  The concept of risk factor can be used to 
study the  cause or  pathophysiology of  CVD,  to  estimate  the  total  cardiovascular  risk,  to 
understand the dynamics of the CVD epidemic within and between populations.  Absolute 
cardiovascular risk is the probability that a person or a group of persons will develop CVD 
over a fixed period of time.  Relative risk is generally expressed as a ratio comparing a person 
or  a  group  of  persons  with  another  person  or  group  of  persons  that  differ  in  terms  of 
exposure.  Relative risk is of great scientific interest.  It says about the strength of association. 
However, in terms of public health, absolute risk is also very important - a given relative risk 
reduction will end up in many more  end points avoided if applied to a group of subjects at 
high absolute risk than one at low absolute risk.
Risk factors can be identified by means of cross sectional  or case-control  studies. In the 
INTERHEART  study22  it was reported that a limited set of risk factors – abnormal lipids, 
smoking,  hypertension,  diabetes, abdominal  obesity,  psychosocial  factors,  consumption of 
fruits, vegetables and alcohol, and regular physical activity account for most of the risk of 
myocardial infarction worldwide in both sexes and at all ages in all regions.  The levels of 
these risk factors have increased steeply in most non – Western countries over the past two 
decades. Although there are some differences among the ethnic groups in the interactions 
between the genes and environment ,  the available evidence indicates that the main risk 
factors for CVD are relevant to all populations and that most of the risk is environmentally 
determined.
Age
 Age is one among the strongest cardiovascular risk.   Its relationship with cardiovascular 
mortality  is  exponential.   It  is  an  important  factor  to  consider  in  total  cardiovascular  risk 
estimation, but its non modifiable nature limits its use in the management of cardiovascular 
risk.  Given the nature of its association with CVD, it explains the paradox that if prevention of 
CVD  is  successful  in  a  given  generation,  total  cardiovascular  mortality  will  increase  by 
preventing premature deaths, a larger proportion of the population will grow old and enter the 
elderly age group where death is attributed to CVD in a majority of cases.  In fact, the number 
of people >60 years of age is expected to double by 2025 and to triple by 2050 globally23 . 
The proportion of this aged population is likely to increase more in the Asian-Pacific region; 
thus, half of the world’s cardiovascular burden is predicted to occur in this area24 .
Sex
Total cardiovascular risks in women tend to resemble those of men of 10 years younger. 
Thus, risk is merely deferred by 10 years and ultimately more women than men die from 
CVD.  The apparent protection of women from CVD is a myth – 40% of women die from CVD, 
compared with 3% of deaths from breast cancer.  Of 17.5 million persons worldwide dying 
from CVD each year, over 8.6 million are women.  Ischemic heart disease (IHD) presents 
later in women, who are therefore older and more likely to suffer from co-morbidities such as 
diabetes and hypertension.  Women with diabetes develop CVD at the same time in life as 
men,  canceling  out  the  10-year  protection  effect  afforded by female  hormones.   Specific 
hormone-related  risk  factors  include polycystic  ovarian  syndrome,  premature  menopause, 
and gestational diabetes or hypertension. Female sex hormones are potent modulators of 
cardiac risk factors at virtually every level of the atherosclerotic process.  CHD and stroke are 
rare before menopause.  However,  hormone replacement therapy has failed to show any 
benefit  in  terms of  CVD risk reduction in  women, mainly because of  associated adverse 
effects.   Current  risk  estimation  systems  underestimate  the  problem,  especially  by  not 
accommodating  older  women.   There  is  therefore  a  pressing  need  to  to  ensure  that 
cardiovascular trials are specifically designed to incorporate sufficient numbers of women to 
allow gender specific efficacy analyses to be undertaken.
Family history of cardiovascular disease
It is defined as history of premature CVD in a first degree male relative <55 years of age and 
female relative <65 years.   Although the odds ratio  for  an  acute  myocardial  infarction  in 
people with a family history was about 1·5, the PAR  rose from 90% with the nine potentially 
modifiable risk factors to 91% with the addition of family history22  .  This finding suggests that 
a large part of the effect of family history might be mediated through known risk factors, which 
could  be  affected  by  both  shared  lifestyles  and  genetic  factors  rather  than  through 
independent pathways.
A special group of non modifiable risk indicators relate to existing CVD in a given person. 
Patients with established CVD are at high risk of recurrent events, but indicators of existing 
vascular damage in asymptomatic subjects  can also help in the identification of  high risk 
groups in the community.  Different techniques such as the ankle-brachial index, the intima-
media thickness of the carotid artery, calcium deposits in the coronary arteries identified by 
CT scan and left ventricular wall motion abnormalities identified by echocardiography have 
been recommended to identify this high risk group. These tests can be of help in developing 
strategies for prevention of CVD.
Modifiable risk factors 
They can in principle be prevented, changed or controlled. Modifiable risk factor per se does 
not equate with reversibility of  CVD.  Major modifiable risk factors include sedentariness, 
smoking, dietary imbalance, impaired glucose tolerance and diabetes mellitus, hypertension, 
dyslipidemia  and  obesity.   Other  factors  which  are  of  importance  includes  psychosocial 
factors  (perceived  stress  at  work,  symptoms  of  depression,  low  socioeconomic  status), 
indicators of chronic inflammation and hemostatic factors.
Tobacco smoking
 In long term smokers, smoking is responsible for 50% of all avoidable deaths and one half of 
these are due to CVD.  The adverse effect of smoking is related to the amount of tobacco 
smoked daily and to the duration of smoking.  The relative mortality from vascular disease 
has been found higher in female smokers than in male smokers and this difference remains 
significant  after  adjustment  for  major  cardiovascular  risk  factors25 .  The  impact  of 
atherosclerotic progression in greater in subjects with diabetes and hypertension and risk of 
future cardiovascular risk is high if smoking starts before age of 15 years.  Passive smoking 
has now been shown to increase the risk of CAD and other smoking related diseases26 . 
Regular exposure to secondhand smoke increases risk of risk of coronary heart disease by 
25%27 .
In the INTERHEART study, it was estimated that smokers and former smokers are at almost 
twice the risk of a myocardial infarction compared with never smokers22 . Smoking accounted 
for  about  36% of  PAR of  acute  myocardial  infarction  worldwide and about  44% in  men. 
Smoking even five cigarettes per day increased risk.  A strong and graded relation was noted 
between numbers smoked and risk of myocardial infarction, with the risk increasing at every 
increment, so that individuals smoking greater than 40 cigarettes per day had an odds ratio of 
9.16.  This finding suggests that there is no safe level of smoking and that if quitting is not 
possible,  the  risk  of  myocardial  infarction  associated  with  smoking  could  be  significantly 
reduced by a reduction in the numbers smoked.  A meta analysis on the effect of smoking 
cessation on mortality after a myocardial infarction showed a mortality benefit with combined 
odds ratio in those who quit of 0.54.   The mortality benefit was consistent regardless of sex, 
duration of follow up, study site and time period28 . 
Smoking increases the risk of atherosclerosis and the occurrence of superimposed thrombotic 
phenomenon.   The latter  effect  may be more  important  as  stopping  smoking  leads to  a 
quicker reduction in the risk of subsequent coronary heart disease events in patients with 
established  coronary  heart  disease  than  in  asymptomatic  individuals.   In  patients  with 
established heart disease, the risk falls within 2 to 3 years to the level of those coronary heart 
disease patients who never smoked, whereas in asymptomatic individuals up to 10 years are 
needed to reach the risk level of those who never smoked.
In  2002,  a  national  survey of  tobacco use reported  that  the  Indian  subcontinent  had an 
alarming rate of current tobacco use of 56 per cent among Indian men aged 12-60 yr29 . 
Reddy  and  colleagues  also  recently  observed  in  a  survey  of  sixth  and  eighth  graders 
attending school in an urban setting that the prevalence of tobacco use (any history of use or 
current  use)  was  2-3  times  higher  among  sixth  graders  compared  with  eighth  graders, 
suggesting a concerning new wave of smoking among India’s youth that forebodes serious 
future public health consequences for the Indian subcontinent30 .   Little data have existed 
regarding the association between the use of other forms of tobacco and the risk of CVD. 
However, a recent analysis of data from the INTERHEART case-control study of risk factors 
for acute myocardial infarction has documented that there is an increased risk of myocardial 
infarction associated with all forms of smoked and smokeless tobacco31 .
Impaired glucose tolerance and diabetes 
 Epidemiological studies have consistently shown a linear relationship between nonfasting 
glucose  values  and  risk  of  developing  CVD.   This  is  confirmed  by  2-hour  oral  glucose 
tolerance test values32 and assay of glycated hemoglobin HbA1c33.  The relationship between 
hyperglycemia and CVD should be considered a continuum.
In diabetes, the relative risk of CVD is of the order of 2 to 3 in men and of 3 to 5 in women, 
while in people with impaired glucose tolerance the relative risk is 1.5 compared with people 
with  normal  glucose tolerance34 .   The INTERHEART study estimated that  15% of  heart 
attacks in Western Europe and 9% of heart attacks in Central and Eastern Europe were due 
to diagnosed diabetes22 .
Subjects with type I diabetes have a 2 to 3 fold high increase in the risk of developing CVD. 
This increased risk is almost entirely confined to patients developing diabetic nephropathy. 
All  type 2 diabetes patients are at increased risk of CVD even in the absence of diabetic 
nephropathy.   Finnish  data  published  in  1998  suggested  that  the  risk  of  developing  a 
myocardial infarction in patients with type 2 diabetes was of the same order as for patients 
without diabetes who had already suffered a first myocardial infarction35 .  This finding had a 
decisive influence on the drafting of treatment guidelines, in which diabetes was labeled as a 
“CVD equivalent” in terms of assessment.  Diabetes also remains an important risk factor for 
mortality in patients with established CVD36 .
Impact of type 2 diabetes on CVD  risk is influenced by a number of factors, including duration 
of diabetes, age and sex37 .  The relative impact of type 2 diabetes on cardiovascular risk is 
stronger in women than in men.  The Indian subcontinent has a higher prevalence of diabetes 
mellitus than any other region in the world, and 2-3 times the reported prevalence in Western 
countries38 .   In India alone, an estimated 19.3 million people had diabetes in 1995, and this 
is  expected  to  almost  triple  to  57.2  million  in  2025  39 .   The  Indian  Council  of  Medical 
Research (ICMR) estimates that the prevalence of diabetes is 3.8 per cent in rural areas, 
compared with 11.8 per cent in urban areas21 .
Hypertension
Hypertension is highly prevalent (20-40% among urban and 12-17% among rural adults)40, 
and  was  affecting  an  estimated  118  million  inhabitants  in  India  in  2000;  this  number  is 
projected to almost double to 214 million in 202541 .
Hypertension  has been identified  as  a  risk  factor  for  CHD,  heart  failure,  cerebrovascular 
disease  and  renal  failure  in  both  men  and  women42 .   Both  systolic  and  diastolic  blood 
pressures show a continuous and graded independent relationship with the risk of stroke and 
coronary events.  Death from both CHD and stroke increases progressively and linearly from 
blood  pressure  levels  as  low  as  115mmHg  systolic  and  75mmHg  diastolic  upward42 . 
Increased risks are present in all  age groups ranging from 40 to 89 years old.  For every 
20mmHg systolic or  10mmHg diastolic increase in blood pressure, there is a doubling of 
mortality from both CHD and stroke42 .   The apparently simple direct relationship between 
increasing systolic  blood pressure and diastolic blood pressure and cardiovascular  risk is 
confounded by the fact that systolic blood pressure rises throughout adult age in the vast 
majority of populations, whereas diastolic blood pressure peaks at about age 60 in men and 
70 in women, and falls gradually thereafter. This observation helps to explain why a wide 
pulse pressure has been shown to in some observational studies to be a better predictor of 
adverse  cardiovascular  outcomes  than  either  systolic  blood  pressure  or  diastolic  blood 
pressure individually.  The contribution of pulse pressure is pronounced after age of 55 years 
of  age41 .   Because  risk  factors  may  interact  positively  with  each  other,  the  overall 
cardiovascular  risk  of  hypertensive  patients  may be  high  even  if  blood  pressure  is  only 
modestly raised.  A high systolic blood pressure may be associated with a lower risk for 
developing  cardiovascular  risk  than  a  low  systolic  blood  pressure,  depending  on  the 
cholesterol level and smoking status – e.g. Mortality is < 10% with a systolic blood pressure of 
180mmhg, but in a non smoker with a total cholesterol of < 5mmol/L while mortality is > 10% 
despite a lower systolic blood pressure of only 120mmHg in the presence of smoking and 
cholesterol elevation. (Data based on SCORE project)42 .
Long  term  observational  data  provide  evidence  that  in  hypertensive  patients  in  whom 
treatment  effectively  controls  blood  pressure,  coronary,  cerebrovascular,  and  overall 
cardiovascular morbidity remains higher than that of normotensive controls.  This may be 
accounted for by factors such as irreversible organ damage at the time treatment is started, 
indicating the need for early identification and management of blood pressure elevation.
Dyslipidemia
The ICMR surveillance project reported a prevalence of dyslipidemia (defined as a ratio of 
total  to HDL cholesterol  >4.5) of 37.5 percent among adults aged 15-64 yr,  with an even 
higher  prevalence  of  dyslipidemia  (62%)  among  young  male  industrial  workers21 .  The 
INTERHEART  investigators  reported  that  the  prevalence  of  dyslipidemia  (abnormal 
apolipoprotein  ApoB/ApoA1 ratio)  among controls without  acute myocardial  infarction was 
higher among study participants living in the five South Asian countries (45%) compared with 
participants from the other 47 countries represented in the study (35%).  As in the overall 
INTERHEART population, abnormal ApoB/ApoA1 ratio was the single largest contributor to 
the  PAR  for  acute  myocardial  infarction  in  South  Asian  countries.   The  impact  of 
dyslipidaemia on the burden of CHD has been otherwise understudied at a population level in 
native South Asians, despite its large contribution to CHD in other world populations.
The prevalence of dyslipidemia is increased in patients with premature CHD: as high as 75 to 
85 percent compared to approximately 40 to 48 percent in age-matched controls without CHD 
43,  44 .   In  the  worldwide INTERHEART study of  patients  from 52 countries,  dyslipidemia 
(defined as a raised apo B to apo A-1 ratio)  accounted for  49 percent of  the population 
attributable risk of a first MI.
Over the entire range of total and LDL cholesterol concentrations there is a strong, continuous 
,  graded,  and independent  positive association  with  risk of  cardiovascular  disease.   This 
association applies to women as well as men, and to old as well as younger people.  The 
relationship  is  exponential,  indicating  that  a  given  absolute  difference  in  total  or  LDL 
cholesterol from any point in the distribution is associated with constant percentage difference 
in coronary heart disease risk.  This association is considerably modified by other risk factors 
such as age, sex, smoking, blood pressure, diabetes and low HDL cholesterol. 
CAD is rare in populations with total cholesterol less than 3 to 4 mmol/L (115-155 mg/dl0, 
even in the presence of other risk factors. Conversely, CAD is inevitable in untreated patients 
with the severest forms of familial hypercholesterolemia, even in the absence of other risk 
factors.  The results of epidemiological studies, as well as trials with angiographic or clinical 
endpoints confirm that the reduction of LDL cholesterol must be of prime importance in both 
primary and secondary prevention of CVD.  A meta-analysis of 38 primary and secondary 
prevention trials found that for every 10 percent reduction in serum cholesterol, CHD mortality 
would be reduced by 15 percent and total mortality risk by 11 percent45 .
Hypertriglyceridemia is also associated with the risk of developing cardiovascular risk, but the 
association is not as strong as it is for hypercholesterolemia. Although the risk of CVD does 
increase with hypertriglyceridemia, the risk is associated with more strongly with moderate 
than  with  severe  hypertriglyceridemia,  probably  because  the  former  is  often  due  to 
accumulation in plasma of triglyceride rich atherogenic intermediate density lipoprotein (IDL) 
and  small  very  low  density  lipoprotein  (VLDL),  whereas  the  latter  can  be  due  to 
nonatherogenic large VLDL and chylomicrons. 
Low concentrations of high density lipoproteins (HDL) are clearly associated not only with 
early development of atherosclerosis, but also with poor outcome in those who already have 
CVD.  The combination of moderately elevated triglycerides and low concentrations of HDL 
cholesterol termed as mixed dyslipidemia is very common in type 2 diabetes and people with 
metabolic syndrome.  It is characterized by a triad of increased concentrations of IDL and 
VLDL, the presence of small dense LDL, and low concentrations of HDL. An increase in 1% in 
HDL is associated with 3% - 5% decrease in risk for women, but only a 2% decrease for 
men46 .
Other lipoproteins 
Lipoprotein A or Lp (a) – It is a low density lipoprotein to which an additional protein called 
apolipoprotein (a) is attached.  It has no known physiological role and high concentrations of 
Lp (a) (arbitrarily >30mg/dl) are largely resistant to modification.  They identify persons at 
increased risk of atherosclerotic disease.
Apolipoprotein  B (apo B) –  It  is  the  major  protein  component  of  LDL,  IDL,  VLDL and 
truncated forms of chylomicrons.  Almost all apolipoprotein B is in atherogenic lipoproteins. 
Concentrations of apo B are therefore a direct measure of the concentration of atherogenic 
lipoproteins in plasma.  The measurement is  a useful  indicator of  risk of  atherosclerosis, 
particularly in patients with hypertriglyceridemia and in people with normal concentrations of 
LDL cholesterol. Values > 150mg/dl are clearly associated with increased risk22 
Apolipoprotein A1 – It is the major apoprotein of HDL. Low concentrations of apolipoprotein 
A1 are, like low HDL cholesterol, associated with higher risk of cardiovascular risk. 
The  apolipoprotein  B/A1  ratio –  This  ratio  beyond  doubt  is  one  of  the  strongest  risk 
markers. This is emphasized in INTERHEART study. This ratio showed a graded relation with 
myocardial infarction risk, with no evidence of a threshold, with an odds ratio of 4.73 for the 
top versus the lowest decile of ApoB/ApoA1 ratio. On the other hand it has been shown that 
the prognostic power does not change when total cholesterol/HDL ratio is replaced by the apo 
B/apo A1 ratio47 .
Total cholesterol/HDL ratio – This ratio if > 5 indicates increased risk and is particularly 
useful in the middle range of the cholesterol distribution (190-250mg/dl). However, this ratio 
does not predict cardiovascular events better than simple total cholesterol measurement42 .
Psychosocial factors 
 There is increasing evidence that psychosocial factors contribute independently to the risk of 
coronary heart disease even after statistical control for the effects of standard risk factors 22, 48, 
49 .   Low socioeconomic status, lack of social support and social isolation, stress at work and 
in family life and negative emotions including depression and hostility have been shown to 
influence both the risk of contracting CHD and the worsening of clinical course and prognosis 
in patients with CHD 50, 51 .  In addition to increasing the risk of first event and worsening the 
prognosis in CHD, these factors may act as barriers to treatment adherence and efforts to 
improve lifestyle, as well as promoting health and well being in patients and populations52 . 
Psychosocial factors may contribute to the early development of atherosclerosis as well as to 
the acute precipitation of myocardial infarction and sudden cardiac death.  The link between 
psychologic stress and atherosclerosis may be both direct, via damage of the endothelium, 
and indirect, via aggravation of traditional risk factors such as smoking, hypertension, and 
lipid metabolism53 .
Obesity
Obesity  is  a  major  risk  factor  for  the  development  of  fatal  and  nonfatal  cardiovascular 
events54 .  Body mass Index (BMI – kg/height in m2) has been extensively used to define 
overweight or obesity.  In adults, overweight is defined by an increased BMI ranging from 25 
to 29.9 and obesity by BMI  > 30.  Increasing BMI is highly associated with CVD.  Increased 
body mass index (BMI) is associated with a higher risk of acute myocardial infarction55 .  This 
association  is,  however,  attenuated  or  disappears  after  adjustment  for  metabolic  factors, 
indicating the important indirect role of overweight and obesity.  Other indicators apart from 
BMI have been proposed to assess body fat distribution.  The waist-hip ratio (WHR) and waist 
circumference (WC) are now frequently used.  Both the World Health Organisation (WHO) 
report on obesity56  and the American national Heart, Lung and Blood Institute (NHLBI) expert 
panel on obesity57  recommend the use of WC as an additional indicator of cardiovascular 
risk.  WC >102cm in men and >88cm in women is the threshold at which weight reduction is 
advised.   Waist  and hip  circumference is  measured with  a  nonstretchable  standard  tape 
measure. Waist measurements are obtained over the unclothed abdomen at the narrowest 
point between the costal margin and iliac crest, and hip circumferences over light clothing at 
the level of the widest diameter around the buttocks22 .  In healthy subjects, WC is a better 
predictor of acute coronary events than BMI58 . 
Obesity paradox
 In patients with AMI, high BMI appears to have an unexplained protective effect on survival 
59-60 .   In patients with CAD, BMI does not adequately discriminate between body fat and lean 
body mass and may thus help to explain the controversy known as the obesity paradox61 . 
The major impact of younger age in the apparent protection conferred by obesity also has 
been  reported  in  most  recent  studies59,62  .Young  age  may  drive  an  increased  use  of 
medications and procedures, a factor that may have a favorable impact on outcomes.
Lifestyle factors
A diet  rich in  calories,  saturated fat,  and cholesterol  contributes to other  risk factors that 
predispose to CHD.  Weight gain promotes the major cardiovascular risk factors and weight 
loss  improves  them.   Epidemiologic  data  indicate  that  moderate  alcohol  intake  has  a 
protective effect on coronary heart disease63, 64 .  In addition to the amount of exercise, the 
degree of cardiovascular fitness (a measure of physical activity), as determined by duration of 
exercise and maximum oxygen uptake on a treadmill, is also associated with a reduction in 
CHD risk and overall and cardiovascular mortality65 .  After adjustment for age, peak exercise 
capacity, measured in metabolic equivalents (METs), was a stronger predictor of mortality 
than other established cardiovascular risk factors among men with and without CVD.  For 
each  one  MET  increase  in  exercise  capacity,  there  was  a  12  percent  improvement  in 
survival66 .  Exercise may have a variety of beneficial effects including an elevation in serum 
HDL-cholesterol, a reduction in blood pressure, less insulin resistance, and weight loss.
There  is  growing  evidence  suggesting  that  fruit  and  vegetable  consumption  is  inversely 
related to the risk of CHD and stroke67 .   The INTERHEART study found that lack of daily 
consumption of fruits and vegetables accounted for 14 percent of the PAR of a first AMI.  High 
fiber intake is also associated with a reduction in the risk of CHD and stroke compared to low 
intake.  In two studies of male and female health professionals, a 10 g increase in total daily 
dietary fiber intake was associated with a relative risk for MI of 0.8168 .
Universal definition of myocardial infarction69
From the epidemiological point of view, the incidence of myocardial infarction in a population 
can be used as a proxy for the prevalence of CAD in that population.  It is an indicator of one 
of the leading health problems in the world, and it is an outcome measure in clinical trials and 
observational studies. With these perspectives, myocardial infarction may be defined from a 
number  of  different  clinical,  electrocardiographic,  biochemical,  imaging,  and  pathological 
characteristics.
A universal  definition for  myocardial  infarction  would  be of  great  benefit  to  future clinical 
studies in this area since it will allow for trial-to-trial comparisons as well as accurate meta-
analyses involving multiple investigations.  The definition of myocardial infarction employed in 
trials will determine the characteristics of patients entering the studies as well as the number 
of outcome events. Consistency among investigators and regulatory authorities with regard to 
the definition of myocardial infarction used in clinical investigations is essential.
In  general,  the  conceptual  meaning  of  the  term  myocardial  infarction  has  not  changed, 
although new sensitive diagnostic  methods have been developed to  diagnose this  entity. 
Thus, the current diagnosis of acute myocardial infarction is a clinical diagnosis based on 
patient  symptoms,  ECG  changes,  and  highly  sensitive  biochemical  markers,  as  well  as 
information gleaned from various imaging techniques. 
Criteria for acute myocardial infarction
 The  term  myocardial  infarction  should  be  used  when  there  is  evidence  of  myocardial 
necrosis in a clinical setting consistent with myocardial ischemia. Under these conditions any 
one of the following criteria meets the diagnosis for myocardial infarction:
• Detection of rise and/or fall of cardiac biomarkers (preferably troponin) with at least one 
value above the 99th percentile of the upper reference limit (URL) together with evidence of 
myocardial ischemia with at least one of the following:
1. Symptoms of ischemia
2. ECG changes indicative of new ischemia (new ST-T changes or new left bundle 
branch block [LBBB])
3. Development of pathological Q waves in the ECG
4. Imaging evidence of new loss of viable myocardium or new regional wall motion 
abnormality.
•  Sudden,  unexpected  cardiac  death,  involving  cardiac  arrest,  often  with  symptoms 
suggestive of myocardial ischemia, and accompanied by presumably new ST elevation, or 
new LBBB, and/or evidence of fresh thrombus by coronary angiography and/or at autopsy, 
but  death  occurring  before  blood  samples  could  be  obtained,  or  at  a  time  before  the 
appearance of cardiac biomarkers in the blood.
•  For percutaneous coronary interventions (PCI) in patients with normal  baseline troponin 
values, elevations of cardiac biomarkers above the 99th percentile URL are indicative of peri-
procedural myocardial necrosis. By convention, increases of biomarkers greater than 3 × 99th 
percentile  URL  have  been  designated  as  defining  PCI-related  myocardial  infarction.  A 
subtype related to a documented stent thrombosis is recognized.
• For coronary artery bypass grafting (CABG) in patients with normal baseline troponin values, 
elevations  of  cardiac  biomarkers  above  the  99th  percentile  URL  are  indicative  of  peri-
procedural myocardial necrosis. By convention, increases of biomarkers greater than 5 × 99th 
percentile URL plus either new pathological Q waves or new LBBB,
or angiographically documented new graft  or  native coronary artery occlusion, or imaging 
evidence of new loss of viable myocardium have been designated as defining CABG-related 
myocardial infarction. 
• Pathological findings of an acute myocardial infarction.
Criteria for prior myocardial infarction
Any one of the following criteria meets the diagnosis for prior myocardial infarction:
• Development of new pathological Q waves with or without symptoms.
•  Imaging evidence of  a  region of  loss of  viable  myocardium that  is  thinned and fails  to 
contract, in the absence of a non-ischemic cause.
• Pathological findings of a healed or healing myocardial infarction.
Clinical classification of different types of myocardial infarction
TYPE 1 - Spontaneous myocardial  infarction related to ischemia due to primary coronary 
event such as plaque erosion and / or rupture, fissuring, or dissection.
TYPE  2  -  Myocardial  infarction  secondary  to  ischemia  due  to  either  increased  oxygen 
demand or  decreased  supply,  e.g.  coronary artery  spasm,  coronary embolism,  anaemia, 
arrhythmias, hypertension or hypotension.
TYPE 3 - Sudden unexpected cardiac death, including cardiac arrest, often with symptoms 
suggestive of myocardial ischemia, accompanied by presumably new ST elevation, or new 
LBBB, or evidence of fresh thrombus in a coronary artery by angiography and / or at autopsy, 
but  death  occurring  before  blood  samples  could  be  obtained,  or  at  time  before  the 
appearance of cardiac biomarkers in the blood.
TYPE 4a – Myocardial infarction associated with PCI.
TYPE  4b  –  Myocardial  infarction  associated  with  stent  thrombosis  as  documented  by 
angiography or at autopsy.
TYPE 5 – Myocardial infarction associated with CABG.
Reperfusion strategy in STEMI
Prompt  and  complete  restoration  of  flow  in  the  infarct-related  artery  by  thrombolysis  or 
percutaneous coronary intervention is  the mainstay of  management of  acute ST-segment 
elevation myocardial  infarction.  Regardless of  the mode of  reperfusion, the overreaching 
concept  is  to  minimize  total  ischemic  time,  which  is  defined  as  the  time  from  onset  of 
symptoms of STEMI to initiation of reperfusion therapy. 
Thrombolysis in STEMI
Reperfusion therapy is underutilized in patients with STEMI.  Despite improvements in care, 
up to  one-third  of  patients  presenting with  STEMI within 12 hours of  symptom onset  still 
receive no reperfusion therapy acutely.  In analyses of data from the NRMI-2 database70 , and 
the  GRACE (Global  Registry of  Acute  Coronary Events) study71 ,  factors  associated with 
eligible patients not receiving reperfusion therapy included age  75 years,  female gender, 
presentation without chest pain, and a history of CVD. In addition, the EDQMI (Emergency 
Department  Quality  in  Myocardial Infarction)  study  found  that  failure  to  identify  high-risk 
electrocardiogram (ECG) findings in patients with acute MI was associated with greater odds 
of  ideal  candidates  not  receiving  reperfusion  therapy72. The  2004  ACC/AHA  guidelines 
provide recommendations on selecting a reperfusion strategy for patients with STEMI. The 
first step is to determine time from onset of symptoms, the presence of high-risk attributes, the 
relative risks associated with fibrinolysis, and estimated total time required for achieving PCI 
balloon inflation; these factors logically determine treatment selection. An invasive strategy is 
generally preferred if first door-to-balloon time can be realistically achieved within 90 min if 
there is high risk from STEMI or fibrinolysis is contraindicated73 .  The first of these criteria 
sets an important benchmark, and it should be noted that the goal of performing primary PCI 
within  90  minutes  of  first  medical  contact  represents  the  longest time  that  should  be 
considered acceptable rather than the ideal time frame74 . Yet registry data have shown that a 
door-to-balloon time of <90 minutes is not achieved in the majority of patients undergoing 
primary PCI,  particularly if  transfer is required75,  76.  These data suggest that many STEMI 
patients  are  being denied  the  optimal  treatment  for  prompt  reperfusion.  Fibrinolysis  is 
preferred if <3 hours have elapsed from symptom onset, there is an anticipated delay that 
decreases the potential advantage of PCI, or an invasive strategy is not  an option (e.g., owing 
to  vascular  access  difficulties  or  lack  of  access  to  a skilled  PCI  laboratory  with  skilled 
operators)73 .Thus, within 3 hours of symptom onset, in the absence of delays to initiating an 
invasive strategy, the ACC/AHA guidelines indicate that there is no preference for either PCI 
or fibrinolysis73.  A recent pooled analysis suggested a consistent advantage of primary PCI 
over fibrinolysis regardless of time from symptom onset to presentation77. However, Gersh and 
Antman78  have commented that this conclusion is controversial, and cautioned that analyses 
such as this should not be used as justification for exclusively choosing a strategy of primary 
PCI without  taking into account a realistic  estimate of  the time needed to  implement  this 
strategy in all clinical settings. 
The early-open-artery theory suggests that benefits of reperfusion in patients with STEMI are 
directly  related  to  the  speed  and completeness  with  which  patency of  the  infarct-related 
coronary artery is re-established. Mortality has been shown to be lower among patients in 
whom TIMI flow grade 2 to 3, compared with TIMI flow grade 0 to 1, was achieved within 90 
minutes after  AMI79. This is strongly supported by clinical  studies confirming the important 
relationship  between  achieving  prompt  antegrade  coronary flow  of  the  infarct  artery  and 
improved  clinical  outcomes,  for both  primary  PCI80-84 and  fibrinolysis85-87.  An  analysis  by 
Boersma et  al.  indicated that  the 35-day mortality benefit  associated with early treatment 
equated to 1.6 lives per 1,000 patients per hour of delay from symptom onset to treatment, 
with even more of an impact of time in the early hours86. However, the recent Occluded Artery 
Trial  showed that PCI provided no delayed benefit  over  optimal  medical  therapy alone in 
stable patients with persistent total occlusion of the infarct-related coronary artery 3 to 28 days 
after AMI who met criteria for high risk88,  indicating that there is no indication to open an 
occluded vessel outside the therapeutic window in an asymptomatic patient following STEMI.
In theory the ideal figure for the use of thrombolytic therapy is the sum of patients eligible on 
ECG criteria minus those who have clear contraindications for treatment, either because of 
perceived risk of bleeding or if the delay after the onset of symptoms is excessive. In practice 
this  figure  is  not  easily  determined  because  neither  cardiographic  appearances  nor 
contraindications are categorical variables and are subject to individual interpretation.  In one 
UK based study89 of 13628 patients with a final  diagnosis of definite myocardial  infarction 
75.7% were considered eligible for thrombolytic therapy. Of these 85.9% were administered 
thrombolytic therapy and 14.1% were considered late for thrombolytic therapy or had clinical 
contraindications.
The most common thrombolytic agents have been streptokinase (first generation thrombolytic 
agent) and alteplase (tissue type plasminogen activator, t-PA, second generation thrombolytic 
agent). In the meantime, third generation thrombolytic agents have reached clinical practice. 
Many of them are derivatives of alteplase, the current gold standard for thombolytic therapy in 
acute  coronary syndromes with  STEMI.  The most  prominent  among them are  reteplase, 
tenecteplase,  and  lanoteplase.  Reteplase  (recombinant  plasminogen  activator,  r-PA)  is  a 
single chain deletion mutant of alteplase that is expressed in Escherichia coli and, therefore, 
is expressed as an unglycosylated protein. Reteplase includes 355 amino acids with a total 
molecular weight of 39 kDa. The molecule consists of cringle 2 and the protease domain of 
the alteplase molecule.  Because of the deletion of the fibronectin finger region, the binding of 
reteplase to  fibrin  is  significantly reduced in comparison with  that  of  alteplase.   Although 
kringle  2  (known to  stimulate  protease in  the  presence of  fibrin)  is  part  of  the  reteplase 
molecule, reteplase is stimulated in the presence of fibrin to a lower extent than alteplase, 
suggesting that the fibronectin finger is involved in the stimulation of the protease as well. 
Reteplase, in comparison with alteplase, is characterised by reduced fibrin selectivity.  In the 
absence  of  fibrin,  reteplase  and  alteplase  do  not  differ  with  respect  to  their  activity  as 
plasminogen activators, nor do they differ with respect to their inhibition by the plasminogen 
activator inhibitor type 1 (PAI-1).  Tenecteplase is also called the TNK-mutant of alteplase. 
The molecule does not constitute a deletion mutant of alteplase (as reteplase does).  Instead, 
it consists of the alteplase molecule with the exception of three point mutations.  At position 
103 of the polypeptide the amino acid threonine has been replaced by asparagine leading to 
a  new glycosylation site.   The carbohydrate  chain that  is  linked to  this  site  enlarges the 
molecule, thereby reducing its elimination and prolonging its plasma half life.  At position 117, 
asparagine  has  been  replaced  by  glutamine.   By  the  exchange  of  this  amino  acid  the 
carbohydrate  side  chain  that  facilitates  hepatic  elimination  has  been  removed.   Hence, 
plasma half life is further prolonged.  Finally,  at position 296–299 the amino acids lysine, 
histidine,  arginine,  and  arginine  have  been  replaced  by  four  amino  acids  alanine. 
Consequently, the inhibition by PAI-1 is reduced 80 times in comparison with alteplase.  In the 
ASSENT-1 (assessment of safety and efficacy of a new thrombolytic agent) trial in patients 
with AMI,, single bolus tenecteplase proved to be as safe as the gold standard of thrombolytic 
therapy, the accelerated regimen of alteplase (initial bolus followed by an infusion over 90 
minutes)90.   In  the  TIMI-10B  (thrombolysis in  myocardial  infarction)  trial  single  bolus 
administration of 40 mg tenecteplase achieved the same rate of patency at 90 minutes after 
the initiation of thrombolytic therapy as alteplase in the accelerated regimen did91 .  In the 
ASSENT-2 trial tenecteplase and alteplase were equal with respect to total mortality after 30 
days 92.
The  plasminogen  activator  lanoteplase  (novel  plasminogen  activator, n-PA)  is  another 
deletion  mutant  of  the  alteplase  molecule that  also  exhibits  an  additional,  single  point 
mutation. In comparison with alteplase the fibronectin finger region and the epidermal growth 
factor domain have been deleted in  the lanoteplase molecule.  In addition, in kringle 1,  at 
position 117 the amino acid asparagine has been replaced by glutamine. Because of this point 
mutation the glycosylation site that is responsible for  facilitated hepatic elimination is lost. 
Consequently, the  plasma  half  life  of  lanoteplase  is  increased.  The  plasma  half  life  of 
lanoteplase is about 10 times that of alteplase and may reach 45 minutes. In the thrombolytic 
treatment of an acute myocardial infarction lanoteplase can be administered as a single bolus. 
In  the  InTIME-1  (intravenous  n-PA  for  treatment  of  infarcting myocardium  early)  trial, 
treatment with 120 kU lanoteplase per kg body weight resulted in a higher patency rate of the 
infarct related coronary artery at 90 minutes than treatment using alteplase in the accelerated 
regimen93 .  However, with respect to overall mortality at 30 days lanoteplase and alteplase 
were equally effective (InTIME-2 trial)94.
Combination therapy 
In  the  field  of  reperfusion  therapy  in  acute  myocardial  infarction, the  term  "combination 
therapy"  is  most  often used to  describe the combined use of  reduced dose plasminogen 
activators and full  dose glycoprotein (Gp) IIb/IIIa inhibitors.  The latter block the Gp IIb/IIIa 
receptors at  the surface of activated platelets and, subsequently,  platelet aggregation, the 
major mechanism in reocclusion.  Since the activated receptor constitutes the final common 
pathway  of  platelet  activation,  the  Gp  IIb/IIIa inhibitors  form  the  most  potent  antiplatelet 
therapy now available. Among them abciximab, eptifibatide, and tirofiban have proven their 
clinical efficacy.  
In the TIMI 14 trial alteplase at half dose (15 mg as an initial bolus, 35 mg as an infusion over 
60 minutes) combined with abciximab at full dose (0.25 mg/kg as an initial bolus, 10 µg/min as 
an infusion over 12 hours) yielded the highest patency rate 90 minutes after the initiation of 
treatment  (TIMI  3  flow  in 76% of  treated  patients)  without  increasing  the  risk  of  severe 
bleeding  complications95 .   In the  SPEED  (strategies  for  patency  enhancement  in  the 
emergency department) trial a patent coronary artery could be achieved more often with the 
combination of reteplase in half dose (a double bolus of 5 U each, 30 minutes apart) and 
abciximab in full dose than with reteplase in full dose alone96. However, in the GUSTO V trial 
the higher patency rate of this regimen could not be translated into reduced mortality after 30 
days97. In the ASSENT 3 trial half dose tenecteplase combined with abciximab was compared 
with full dose tenecteplase alone98. With respect to the primary end point (a composite end 
point combining 30 day mortality, in-hospital re-infarction, or in-hospital refractory ischemia), 
the combination therapy was superior to monotherapy with plasminogen activator but without 
Gp IIb/IIIa inhibitor, although with higher bleeding rates with combination therapy. Double-
bolus eptifibatide (180/2/180) plus half-dose TNK tended to improve angiographic flow and 
ST-segment  resolution  compared with  TNK  monotherapy  but  was  associated  with  more 
transfusions and non-cerebral bleeding99 . 
Primary PCI in STEMI 
 Treatment of acute STEMI has undergone a major revolution over the past 15 years, with the 
recognition that intracoronary thrombosis is the final mechanism of vessel occlusion and the 
understanding that  the prompt reestablishment  of  vessel  patency offers significant  clinical 
benefits100, 101.  Widely used thrombolytic regimens currently achieve complete reperfusion by 
90 minutes in about 55% to 60% of cases and partial reperfusion in an additional 20 % to 
25%102.  Atleast 10% of vessel opened by thrombolysis either reocclude or cause recurrent 
angina during hospitalization owing to persistence of an underlying high grade atherosclerotic 
stenosis.
Primary  PCI  refers  to  the  use  of  angioplasty  to  achieve  reperfusion  in  patients  with  ST 
elevation  myocardial  infarction  instead  of  thrombolysis.  Primary  PCI  generally  yields 
significantly higher rates of complete reperfusion than does thrombolytic therapy. In addition, 
the underlying coronary stenosis, a substrate for recurrent ischemia is relieved early in the 
course of the infarction. The potential of theses attributes of PCI to improve clinical outcome 
beyond that achievable with thrombolytic therapy has led to randomized control clinical trials 
directly comparing these two approaches.
Initially  suitable  only  for  highly  selected  low  risk  patients,  percutaneous  coronary 
revascularization has evolved into a vital component of the management of acute coronary 
syndromes  (ACS).   Remarkable  advances  in  catheters,  stents,  adjunctive  pharmacologic 
therapy, imaging and operative techniques have expanded the application of percutaneous 
coronary  intervention  to  patients  with  clinically  and  anatomically  complex  coronary  heart 
disease.
The largest single trial of this type GUSTO II B compared direct angioplasty and accelerated 
tissue plasminogen activator  (tPA) therapy in 1138 patients103.   The primary end point  (a 
composite of death, non fatal reinfarction or nonfatal disabling stroke at 30 days) occurred in 
9% of the angioplasty group and 13.7% in the tPA group (p=0.03) for a 33% risk reduction.  A 
secondary analysis at 6 months still favoured angioplasty, although the difference between 
the 2 strategies was no longer statistically significant (primary end point occurred in 14.7% of 
angioplasty patients and 16.1% of tPA patients).
A meta analysis of GUSTO II B and 9 other randomized trials comparing direct angioplasty 
and various thrombolytic regimens also supports the superiority of direct PCI when practiced 
in centres with on site coronary catheterization104 .  The widely used end point of 30 day 
mortality or re-infarction was significantly lower among patients treated with direct PCI than 
among those given thrombolytic therapy.
There has been a concern regarding the safety of stents in the highly thrombotic setting of 
STEMI. Direct angioplasty with stenting has been tested against balloon angioplasty alone in 
randomized trials105, 106 .   In the Stent PAMI study105  , the prespecified primary 6 month end 
point  (  a  composite  of  death,  nonfatal  myocardial  infarction,  stroke  or  target  vessel 
revascularization)  occurred  less  frequently  with  stenting  than  without  stenting  (12.6% vs. 
20.1%, P<0.01).
It  has  been  suggested  that  vigorous  plaque  and  thrombus  compression  associated  with 
primary  PCI  in  general  and  stent  deployment  in  particular  may  increase  athero  and 
thromboembolic  plugging  of  downstream  microvessels.  Such  a  phenomenon  could 
paradoxically increase infarct size. This has led to the investigators testing the administration 
of  glycoprotein  IIb/IIIa  inhibitors  during  PCI.   Studies  have  shown  that  the  addition  of 
glycoprotein IIb/IIIa inhibitors during stent based primary PCI do indeed improve coronary 
blood flow and reduce infarct size107-109.
A comprehensive review by Keeley and colleagues included 23 trials in a meta analysis110.  It 
showed that  Primary PTCA was better than thrombolytic therapy at reducing overall short-
term death (7%  vs. 9%; p=0·0002),  non-fatal reinfarction (3% vs. 7% ; p<0·0001), stroke (1% 
vs.  2% ;p=0·0004), and the combined endpoint of death, non-fatal reinfarction, and stroke 
(8%  vs. 14% ; p<0·0001).  The results seen with primary PTCA remained better than those 
seen with thrombolytic therapy during long-term followup, and were independent of both the 
type of thrombolytic agent used, and whether or not the patient was transferred for primary 
PTCA.
2007 focused update of the ACC/AHA 2004 Guidelines for the management of patients with 
STEMI states that all patients diagnosed to have STEMI presenting to a hospital with PCI 
capability should be treated with primary PCI within 90 minutes of first medical contact as a 
systems goal (Class IA).  STEMI patients presenting to a hospital without PCI capability and 
who cannot be transferred to a PCI centre and undergo PCI within 90 minutes of first medical 
contact should be treated with fibrinolytic therapy within 30 minutes of hospital presentation 
as a systems goal unless fibrinolytic therapy is contraindicated (Class IB)111 .
METHODOLOGY
This is an observational study done in 150 consecutive patients who presented with acute 
STEMI between November 2008 to January 2009 to the accident and emergency department 
and chest pain unit of a tertiary care centre in a district capital in South India.
Inclusion criteria
Patients aged > 18 years and presenting within 7 days of acute ST-segment elevation 
myocardial infarction were included.
Exclusion criteria
Patients aged < 18 years
Patients presenting after 7 days of acute ST-segment elevation myocardial infarction
Patients presenting with non ST-segment elevation myocardial infarction or unstable angina.
Demographic profile
Demographic data including age, sex and socioeconomic status of the patients were 
recorded.  Socioeconomic score was obtained according to modified Kuppuswamy’s 
socioeconomic status scale and the patients were stratified into 5 groups accordingly112.
Patient’s symptoms at the time of presentation were noted.  The place of first medical contact 
was  recorded  as  whether  it  was  the  local  practitioner  /  the  government  hospital  or  the 
accident and emergency unit/ chest pain unit of the tertiary care centre.
Assessment of time delays in presentation of STEMI
Pre-hospital delay was defined as the time between the onset of symptoms suggestive of 
acute coronary disease and arrival at the accident and emergency department / coronary care 
unit113.  The time delay from onset of symptom to that of presentation to any hospital was 
recorded.  If the patient had presented to the local practitioner/government hospital initially, 
the time delay of transport form the first referral center to the tertiary care hospital was also 
recorded.    The pre-hospital delay was taken as the total time delay from onset of symptoms 
to final presentation at the accident and emergency unit or the chest pain unit of the tertiary 
care centre.  The door-to-needle time for thrombolytic therapy and door-to-balloon time were 
recorded for primary PCI.   The time delay for  transfer from the accident  and emergency 
department of the tertiary care centre to the chest pain unit was also recorded.  All patients 
who were  thrombolysed  elsewhere  but  presenting  to  the  tertiary  care  hospital  for  further 
management within 7 days of STEMI were also included in the study. 
Risk factor profile
The  risk  factor  profile  of  patients  including  diabetes,  hypertension,  smoking  status,  past 
history of ischemic heart disease, family history of ischemic heart disease, dyslipidemia and 
postmenopausal status in case of female sex was recoded.  Smoking status was recorded as 
non smoker or former smoker or current smoker. Current smokers were defined as individuals 
who smoked any tobacco in the previous 12 months and included those who had quit within 
the past year. Former smokers were defined as those who had quit more than a year earlier. 
Non smokers were who never smoked in their lifetime. 
The  body mass  index  was  calculated  after  measuring  the  height  and  weight  of  patients 
whenever possible. 
Clinical and laboratory profile
The clinical parameters including pulse rate, blood pressure and Killip class at the time of 
presentation was recorded.  12 lead ECG was taken within 10 minutes of presentation or as 
early as possible to the tertiary care centre.  Following criteria was used for the definition of 
STEMI: chest pain of >20 min duration and ST segment elevation >1 mm in at least two 
standard limb leads or >2 mm in at least two contiguous precordial leads or the presence of 
new onset left  bundle branch block in the electrocardiogram. CK-MB and Troponin I were 
subsequently done to confirm diagnosis of  acute myocardial  infarction. 12 lead ECG was 
repeated 90 minutes after thrombolysis and immediately after primary PTCA to calculate ST 
segment resolution.  ST segment resolution >50% was taken as a marker for reperfusion as 
per  2004  ACC/AHA  guidelines114.   The  location  of  MI  was  determined  as  per  the 
electrocardiogram. Laboratory profile including hemoglobin,  total  and differential  white cell 
counts, AC, PC ,  lipid profile within 24 hours of myocardial  infarction, cardiac enzymes – 
troponin I and CK-MB, creatinine was measured.  2D echocardiography was done during the 
course of hospital stay and cardiac internal dimensions, ejection fraction, diastolic function 
were recorded and presence or absence of mechanical complications assessed. 
Management strategy
 All patients were given options of primary PCI and thrombolysis whenever appropriate and 
treatment strategy was initiated after patients consent for the appropriate strategy.  Patients 
were treated conservatively if they were not eligible for thrombolysis and were not willing for a 
primary PCI.  If the patient opted for thrombolysis, it was done using either streptokinase or 
tenecteplase which was decided after giving the options of both to the patient and according 
to financial affordability.  Primary PCI was done using standard protocol and stents implanted 
whenever indicated.  
All patients were given standard pharmacotherapy which included aspirin, clopidogrel, beta 
blockers and angiotensin converting enzyme inhibitors (if  not contraindicated) and statins. 
Other drugs such as nitrates, diuretics, digoxin and angiotensin receptor blockers were used 
appropriately as per clinical needs.  Temporary pacemaker insertion was done when deemed 
appropriate.  Patients were given anticoagulant therapy whenever clinically indicated and the 
type of anticoagulant therapy was recorded. 
Assessment of in-hospital outcomes
 All  patients were monitored in hospital  for clinical  outcomes including mortality,  recurrent 
angina, re-infarction, arrhythmias, heart  failure,  stroke, bleeding, mechanical complications 
and requirement of  rescue PCI.   Coronary angiography and PCI (adjunct  PCI)  was done 
during the hospital stay whenever deemed necessary and at the affordability of the patient. 
Duration of hospital stay was recorded.
Assessment of outcomes at 30 days 
 Patients were followed up at the end of 30 days in the outpatient department and 30 day 
outcomes which included mortality, recurrent angina, re-infarction, heart failure, arrhythmias 
and stroke were recorded.  Patients who did not follow up in the outpatient department at the 
end of 30 days were contacted by telephone or by post and 30 day outcomes obtained.
Statistical analysis
 All data were analyzed using SPSS Software (17.0 versions).  Categorical variables were 
compared by the likelihood ratio Chi-square test or Fisher’s exact test.  Continuous variables 
are presented as mean ± SD and assessed by independent sample T tests.  Predictors of 
pre-hospital  delay were analyzed by logistic  regression.  A probability  value of  <0.05 was 
considered statistically significant.
RESULTS
Over  a  3  month  period  150  consecutive  patients  with  ST-segment  elevation  myocardial 
infarction were enrolled into  this  study.   The results  of  demographic,  socioeconomic, risk 
factor, clinical and laboratory profile, pattern of presentation and management, in-hospital and 
30 day outcomes are presented below.








Age  in years  57±12 56±12 60±10 0.10
Socioeconomic 
Status
Upper    20 (13.3) 14(12) 6(18.2) 0.52
Upper middle 21 (14) 17(14.5) 4(12.1) 0.94
Lower middle 63 (42) 48(4.1) 15(45.5) 0.79
Upper lower 33 (22) 26(22.2) 7(21.2) 0.93
Lower 13 (8.7) 12(10.3) 1(3) 0.39
Data are number (%) or mean + SD.
Table 2: Place of first medical contact
N (%)
Local practitioner / primary/ secondary 
care hospital
107 (71.3)
A&E of tertiary care centre 19 (12.7)
Chest Pain Unit of tertiary care centre 24 (16)
A&E – accident and emergency unit
Table 3: Pre-hospital delay, door-to-needle time, door-to-balloon time
Total   Male Female p
Time to first contact 308 ±577  249 ±459 520±854 0.01
Pre-hospital delay 403±589 3522±92 39±9335 0.08
D2N time 55±51 49±52 39±47 0.88
D2B time 87±32 83±34 95±29 0.56
A&E to CPU 63±44 60±44 71±42 0.34
Local Hospital to CMC 158±151 147±145 192±165 0.17
All data are Mean + SD (in minutes), D2N – door-to-needle time, D2B- door-to-balloon time, 
A&E – accident and emergency unit of tertiary care centre, CPU – chest pain unit of tertiary 
care centre.
The  median  pre-hospital  delay  was  4  hours.   The  median  door-to-needle  time  was  45 
minutes.  The median door-to-balloon time was 92 minutes. The mean pre-hospital delay in 
hours was 6.7±9.8 hours. The mean pre-hospital delay in hours for men and women were 
5.5±7.9 hours and 10.8±13.9 hours respectively (P=0.003).  After excluding all patients who 
presented later than 12 hours, the mean pre-hospital delay was 4.5±3.1 hours and the mean 
pre-hospital  delay  in  men  and  women  was  4.3±3.1  hours  and  5.2±3.2  hours 
respectively(P=0.205)
Skewness and Kurtosis  value for  pre-hospital  delay was 4.761 (SE 0.198)  and 27.9 (SE 
0.394) respectively.
Table 4: Comparison of door to needle time among patients presenting initially to A&E / Chest Pain 
Unit of tertiary care centre
A&E of tertiary 
care centre






Door to needle time 
  Mean +SD
65.3±39.1 32.1±39.1 0.017
A&E – accident and emergency unit of tertiary care centre
Table 5: Characteristics associated with prolonged Pre-hospital delay
Characteristics Pre-Hospital Delay
< 6 Hours                > 6 Hours
n=100                     n=50
P value OR (95% CI)
Women 16(16) 17(34) 0.012 2.7(1.2-5.9)
Age in years 
(mean ±SD) 58±12 56±11 0.385
Diabetes 
Mellitus 49(49) 24(48) 0.908 1.04(0.53-2.05)
Hypertension 46(46) 18(36) 0.243 1.51(0.75-3.05)
Smoking 33(33) 18(36) 0.715 0.8(0.43-1.79)
Family history 
of IHD 4(4) 1(2) 0.520 2.04(0.22-18.7)
Past history of 
IHD 7(7) 0(0) 0.05 1.53(1.36-1.73)
Location of MI 0.84
Anterior wall 49(49) 27(54) 0.68
Inferior wall 47(47) 21(42) 0.68
Lateral wall   4(4)   2(4) 1.0
BMI 0.771
<18.5 4(4.5) 3(6.7) 0.91
18.5-24.9 52(59.1) 28(62.2) 0.87
25-29.9 27(30.7) 13(28.9) 0.98
>30 5(5.7) 1(2.2) 0.63









Chest pain 147 (98) 116(99.1) 31(93.9)  0.059
Dyspnoea 24(16) 16 (13.7) 8(24.2)  0.144
Palpitation 4(2.7) 4(3.4) 0(0) 0.28
Giddiness 12(8)          10(8.5) 2(6.1) 0.64
Syncope 2(1.3) 1(0.9) 1(3) 0.33
Sweating 44(29.3) 32(27.4) 12(36.4) 0.31
Vomiting 14(9.3)          17(15) 2(6) 0.31
Table 7: Risk factor profile







Diabetes Mellitus 73(48.7) 49(41.9) 24(72.7) 0.002
Hypertension 64(42.7) 46(39.3) 18(54.5) 0.18
Smoking 51(34) 50(42.7) 1(3) 0.00
Family History of IHD 5(3.3) 4(3.4) 1(3) 0.91
Past History of IHD 7(4.7) 6(5.1) 1(3) 0.61
Dyslipidemia 1(0.7) 1(0.9) 0(0) 0.59
Post Menopausal 0(0) 29(88) -
No risk Factors 21(14) 20(17.1 1(3) 0.04
Figure 1.  Risk factor profile
 












Table 8: Body mass index 
BMI Frequency (%) Male Female p
Mean 23 ± 6 23.9±2.8 23.9±3.9 0.976
<18.5  7 (5.2) 5(4.8) 2(7.1) 0.98
18.5-24.9 80 (60.1) 63(60) 17(60.7) 0.94
25-29.9 40  (30.0) 33(31.4) 7(25) 0.66
>30 6 (4.5) 4(3.8) 2(7.1) 0.81
BMI of 23.0 has been identified as the cut off in Asians for predicting the risk of CVD. The 
number of patients who had a BMI of greater than 23.0 was 85(56%).
Table 9: Location of myocardial infarction
N (%)
ANTERIOR 76 (50.7)
              ASMI 33(22)
              EXTENSIVE AWMI 43(28.7)
INFERIOR 68(45.3)
              INFERIOR 9(6.0)
              INFERIOR+RVMI 26(17.3)
              INF+RV+PWMI 10(6.7)
              INF+PWMI 23(15.3)
LATERAL 6(4.0)
              LATERAL 3(2.0)
              PW + LWMI 3(2.0)
The most common location of acute myocardial infarction involved the anterior wall. Inferior 
wall myocardial infarction, either isolated or associated with right ventricular and / or posterior 
wall was observed in 45.3%. Lateral wall myocardial infarction was rare.
Table 10: Killip class & Ejection fraction.
KILLIPS Frequency (%) Male Female p
I 122(81.3) 100 (85.5) 22(66.7) 0.02
II  8(5.3) 5(4.3) 3(9.1) 0.51
III 8 (5.3) 4(3.4) 4(12.1) 0.12
IV 12 (8.0) 8(6.8) 4(12.1) 0.53
EF 45 ± 9 45.1± 9 46.3 ± 8 0.51
Data are number (%) or mean ± SD.
Table 11: Laboratory profile
Mean± SD Male Female p
Hemoglobin 13. ±72.3 14. ±51.9 11.3±1.9 0.00
Total count 13108±4818 1305±84956 13279±4392 0.81
AC 160±65 15±662 17±474 0.18
PC 18±686 181±81 206±100 0.16
Creatinine 1.0±80.33 1.07±0.27 1.1±50.50 0.22
Troponin 34. ±857 30±55 51±61 0.07
CKMB 98±95 96±95 103±95 0.70
Total Cholesterol 190±43 188±37 199±59 0.19
TG 161±106 15±281 191±168 0.08
HDL 35±9 34±7 37±14 0.07
LDL 12±237 121±33 12±749 0.45
Newly detected DM 8(5.3) 8(7.1) 0 0.12
Newly detected 
Dyslipidemia
106(70.7) 85(76.6) 21(65.6) 0.21
Data are number (%) or mean ± SD.
Women had significantly lower levels of hemoglobin. Troponin levels at time of presentation 
were significantly higher in females. About 70% were newly diagnosed to have dyslipidemia 
based on LDL level > 100mg/dl.










Figure 2. Management strategy*
   
* - Number in pie chart represents percentages
Table 13: Comparison of management strategy with respect to pre-hospital delay 
                                    Pre-Hospital Time delay in hours
Management 
Strategy <6 6-12 >12
Thrombolysis





Data are number (%) of patients




< 50 > 50 p
N (%) 53 (35.3) 89(59.3)
Pre-hospital delay 0.02
    <6 hours 33(62.3) 66(74.2) 0.19
      6-12 hours 11 (20.8) 20(22.5) 0.97
    >12 hours 9(17) 3(3.4) 0.01
Reperfusion strategy 0.09
Thrombolysis 47(38.2) 76(61.8) 0.76
Primary PTCA 1(9.1) 10(90.9) 0.09
Table 15: Coronary angiography findings
N (%)
CAG at index admission 28 (18.7)




Type of stent used 24(85)
DES 3(12.5)
BMS 21(87.5)
SVD- single vessel disease, DVD – double vessel disease, TVD- triple vessel disease
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                   LMWH 32(21.3)
Fondaparinux 8(5.3)
                   None 103(68.7)
Figure 3.  Comparison of prescription of medical therapy between earlier study* and 
present study
* -  Jose et al 115
Earlier study 
















                  
 Figure 4.    In-hospital Complications* 
* - Number in pie chart represents percentages
Table 18: Duration of hospital stay                                
                                                     Duration of Hospital stay in days
Management 













Age (Mean±SD) 60±12 0.19
Male 12 (67) 0.35
Diabetes Mellitus 9 (50) 0.91
Hypertension 7 (39) 0.73
Smoking 4 (22) 0.26
Pre Hospital delay >6 hrs 5 (28) 0.59
Management Strategy 1.0
Thrombolysis 16 (88) 0.76
Primary PCI 1 (6) 0.75
Conservative 1 (6) 0.95
ECG ST resolution <50% 9 (50) 0.002
Ejection Fraction (in %) 34.6±8.1 <0.002
Data are number (%) or Mean±SD
The mean ejection fraction in those who survived is 46.1±8.4%. The mean age in those who 
survived is 56.6±11.4 years.
Table 20: Causes of In-hospital Mortality






Heart Failure 11(61) 6(5.1) 5(15)
Arrhythmias VT/VF 3(16.6) 2(1.7) 1(3)
Suspected 
Myocardial rupture 2(11.1) 2(1.7) 0(0)
Re-infarction/ CHB 1(5.5) 0 1(3)
Ventricular Septal 
Rupture 1(5.5) 1(0.8) 0(0)
Data are number (%)









Lost to follow up 4(2.7)









Diabetes Mellitus 13(65) 33(39.3) 27(58.7) 0.031
Hypertension 9(45) 35(41.7) 20(43.5) 0.955
Smoking 3(15) 29(34.5) 19(41.3) 0.115
Place of first visit 0.044
   Local Hospital 18(90) 60(71.5) 20(63.3)
   A & E 0 (0) 8(9.5) 11(23.3)
  Chest pain Unit 2 (10) 16(19) 6(13.3)
Pre Hospital delay >6 
hours
9(45) 26(31) 15(32) 0.484
Management Strategy 0.133
Thrombolysis 17(85) 70(83.3) 43(93.5)
    Primary PTCA 2(10) 9(10.7) 0(0)
Conservative 1(5) 5(6) 3(6.5)
Coronary Angiogram 4(20) 22(26.2) 2(4.3) 0.004
In hospital Mortality 4(20) 8(9.5) 6(13) 0.377
BMI >25 9(56.3) 24(30.8) 13(33.3) 0.146
Duration of Hospital stay 
<3d
13(65) 44(52.4) 31(67.4) 0.208
Pharmacotherapy
    Aspirin 19(95) 84(100) 44(97.8) 0.18
   Clopidogrel 19(95) 82(97.6) 45(97.8) 0.78
   ACEI 17(85) 73(86.9) 43(93.5) 0.45
   Beta blockers 18(90) 70(83.3) 44(95.7) 0.11
   Statins 19 (95) 78(92.9) 44(95.7) 0.71
Anticoagulation 8(40) 26(31) 13(28.3) 0.636
Table  23:  Comparison  of  baseline  characteristics,  management  strategy  and  in-













        < 6 hrs





Smoking 569(43.1) 51 (34)
Diabetes Mellitus 531(40.2) 73 (48.7)
Hypertension 504(38.2) 64 (42.7)
Past History Of MI 154(11.7) 7 (4.7)
Family History Of MI 128(9.7) 5(3.3)
Location Of MI
        Anterior wall MI






        Thrombolysis





Aspirin 1225 (92.8) 148 (98.7)
ACEI 791 (60.0) 133 (88.7)
Beta blockers 863 (65.4) 132 (88)








Data are number (%) or mean± SD
*- Jose et al 115
                            
DISCUSSION
The demographic characteristics, clinical and risk factor profile, pattern and presentation of 
management of  150 consecutive patients  presenting to  a  tertiary care centre  in a district 
capital in South India with a diagnosis of STEMI were assessed in this study.  The in-hospital 
and 30 day outcomes were also evaluated.
Demographic, symptom and risk factor profile (Table 1, 6, 7 & Figure 1))
The mean age of presentation of STEMI was 57 ±12 years with the majority of them being 
males.  The mean age did not differ significantly among males and females. There is no 
change in the mean age of presentation over the past decade. In the study done by Jose et 
al,115 which  included  patients  from  1999-2003  and  the  CREATE registry9 which  enrolled 
patients from 2001-2005, the mean age has been 56 ±13 years and 57.5 ± 12 years.  Patients 
enrolled in this study presented a decade earlier in comparison to the Western data where the 
mean age of presentation has increased from 64.1 years to 66.4 years4,  116 .   As STEMI 
occurs earlier in this set of population, it can lead to tremendous loss of productive years and 
can have an adverse outcome on the economy as well as national health. 
 Compared to a decade ago, more women have presented with STEMI (16.2% vs. 22%).  But, 
this proportion is considerably lower than the western countries, where the proportion has 
increased  from  32.4%  to  37  %  (P<0.0001)4.   This  may  be  explained  by  the  increased 
emphasis  on  clinical  recognition  of  acute  ischemic  syndromes  in  females117,118.    The 
appropriate use of 12 lead ECG and use of cardiac enzymes, especially troponins, has lead 
to  better  recognition  of  acute  coronary syndromes in  women in  developed countries.   In 
contrast, women in developing countries lack awareness of the risk of cardiovascular disease 
as majority of public health expenditure is devoted to maternal and child health119.  Moreover, 
the use of 12 lead ECG and application of cardiac enzymes would be far less prevalent in 
developing countries leading to underdiagnosis in women. 
Chest pain was the most common symptom at presentation among both males and females, 
but there was a trend for females to present with lesser frequency in comparison with males. 
Sweating and dyspnoea were the next most common symptoms.  There was no significant 
difference  among  the  sexes  based  on  the  symptom of  presentation.   Studies  assessing 
gender differences in symptom of presentation in acute coronary syndrome, have found that 
while men tend to present more with chest pain and diaphoresis, women report significantly 
greater  number  of  symptoms than  men and  have  significantly  more  jaw and  back  pain, 
nausea and / or vomiting, dyspnoea, indigestion and palpitation120, 121.
In  comparison  to  data  derived  from  Western  population4,116,  diabetes  Mellitus  was  more 
prevalent  (48.7% vs.  22.4%),  while  hypertension  was  less  prevalent  (42.7% vs.  56.9%). 
Smoking was equally prevalent in both groups.  There was lesser number of people who 
presented with family history or past history of ischemic heart disease.  Prevalence of patients 
presenting with history of prior CABG or prior PCI has increased in the Western population, 
as revascularization procedures are more widely used in the West.  The increased prevalence 
of diabetes in patients presenting with STEMI is reflective of the epidemic rise in proportion of 
the people with diabetes, obesity and metabolic syndrome.    Compared to men, women who 
presented with STEMI had significantly higher prevalence of diabetes (P = 0.002).  Almost 
90% of the women were postmenopausal.  There was no difference in the prevalence of other 
risk factors apart from smoking which was almost non existent among women.  The increased 
prevalence of diabetes among women presenting with STEMI is reflective of the fact, that 
they are older at the time of presentation and hence more likely to have higher prevalence of 
diabetes, hypertension and obesity.  The presence of diabetes negates the protective effect of 
hormones in females.  
Only 14% of the study population had reported no risk factor at the time of presentation of 
STEMI.  Even among these, nearly three fourth of them were found to have dyslipidemic (LDL 
cholesterol > 100mg/dl) on evaluation of lipid profile at time of hospitalization for STEMI.  This 
supports the fact shown by Canto et al 122 and Greenland et al 123, where approximately 90% 
of the coronary events could be explained by the presence of at least one of the established 
four risk factors and only 10% had to investigate for other markers of cardiovascular risk .
Pre-hospital delay (Tables 2, 3, 4 & 5)
Patients enrolled in this study took much longer to present to the first medical contact from the 
onset of symptom and for definitive treatment to the tertiary care centre.  The mean time 
delay to first medical contact was 308 ± 577 minutes (5.63 ± 9.62 hours) and pre-hospital 
delay was 6.7 ± 9.8 hours.  The median prehospital delay was 4 hours.  After exclusion of 
patients who presented later than 12 hours after symptom onset, the pre-hospital delay was 
4.5 ± 3.1 hours.  Wide geographical variation in the extent of pre-hospital delay has been 
reported  before.   The  shortest  time  was  observed  in  Australia/New  Zealand/USA  and 
CANADA (median of 2.2 hours), the longest delay was seen in Argentina /Brazil (median 4.0 
hours) 124.    Factors associated with greater pre-hospital delay were identified to be elderly 
age, female sex, diabetes mellitus, past history of acute myocardial infarction (AMI).  After 
adjustment  of  confounding  variables,  only age,  DM and past  history of  AMI  emerged as 
strong predictors associated with greater pre-hospital delay125.   45% of patients studies in 
Worcester Heart attack study had presented within 2 hours 125.   However, the proportion of 
patients who presented within 2 hours constitute only 20% of this study group.  There were no 
factors which were predictive of a shorter pre-hospital delay (<2 hours).   Hence, based on 
the mean pre-hospital delay, we categorized patients into 2 groups- those presenting within 6 
hours and those after 6 hours. About 1/3 of the patients took longer than 6 hours to present to 
tertiary care centre. Among these patients, women and patients with past history of ischemic 
heart disease were more likely to present greater than 6 hours. Univariate logistic regression 
analysis  showed that  female sex was the only risk factor  associated with  prolonged pre-
hospital delay {P= 0.012, OR (95% CI) 2.7 (1.2 -5.9)}. 
Rosenfeld et al reported that difficulty in interpreting the severity of symptoms was the factor 
most predictive in women patients who delay seeking care  126.   Health care workers and 
women themselves fail to recognize the early signs of acute coronary syndrome.  Women are 
less likely to be correctly assessed and cared for when symptoms are present.  Women also 
tend to underreport the symptoms and may present with atypical symptoms127  .  Moreover, 
women who present with acute myocardial infarction are older, have greater co- morbidities, 
and are  dependent  on  others  for  seeking  medical  care.   The other  reasons  for  patients 
reaching hospital late include financial constraints, a lack of awareness of the importance of 
the  symptoms,  and  different  types  of  health-care  providers  that  prevent  rapid  access  to 
secondary and tertiary care hospitals  9.  The mean delay from first medical contact to the 
tertiary care centre was 102.5 minutes.  This delay could be shortened by prompt diagnosis 
and referral to the tertiary care centre, training professionals at the primary and secondary 
level hospitals to manage low risk STEMI patients and refer only the high risk patients to 
tertiary care center, especially if undue prolonged transfer time is expected. Western centers 
are well equipped for pre-hospital thrombolysis. But, in developing countries, lack of efficient 
emergency  medical  services  and  trained  paramedic  professionals  does  not  provide  this 
option.  Educating people about cardiovascular risk factors and symptoms, making 12 lead 
ECG and cardiac enzymes widely and cheaply available, training of professionals to diagnose 
promptly, assess risk and refer patients appropriately for reperfusion therapy would reduce 
the pre-hospital delay. 
The  recommended  door-to-needle  time  and  door-to-balloon  time  is  30  minutes  and  90 
minutes respectively.  The median door-to-needle time is prolonged, but the door-to- balloon 
time was near optimally achieved. The median door to needle time was 45 minutes which is 
longer compared to that achieved in US registries128.  The median door- to-needle time and 
door-to-balloon time in NRMI registry in 2006 was 29 minutes and 79 minutes respectively. 
On segregation of patients into those presenting to the accident and emergency department 
initially and those to chest pain unit of the tertiary care centre initially, the door-to-needle time 
was significantly shorter in those presenting to the chest pain unit directly(mean time – 32.1 
+/- 39.1 minutes, P = 0.017).  This was due to the efficient triage system in place in the chest 
pain unit where the patient in attended to immediately by trained staff, a 12 lead ECG taken 
within  10  minutes  of   hospital  arrival  and  availability  of  a  cardiologist  round  the  clock. 
Moreover,  there was a mean time delay of  60 ± 44 minutes associated with  transferring 
patients  from  the  accident  and  emergency  unit  to  the  chest  pain  unit  before  initiating 
thrombolysis.  This emphasizes the rationale and need for set up for such chest pain units 
which could shorten the time delays associated with management of STEMI..
Socioeconomic status (Table 1, 22)
Patients across all the socioeconomic strata presented with STEMI. Though, the lower middle 
class presented in greater numbers, it was not statistically significant.  CREATE registry9  had 
showed increased prevalence of diabetes and hypertension in the rich, higher prevalence of 
smoking in the poor.  However, in this study, we did not find similar results.  Diabetes was 
significantly  less  prevalent  in  the  middle  class  in  comparison  to  the  upper  and  lower 
socioeconomic strata.  There was no difference in prevalence of hypertension or smoking, 
though  relatively  lesser  number  of  upper  class  people  smoked.  Most  of  the  upper  class 
people presented to the local practitioners initially after onset of symptoms, in comparison to 
the middle and lower class people(P = 0.044).  This may possibly be due to the fact that the 
upper class people may have been in regular follow up with their family physicians and may 
have presented to them initially, while those in lower class may not be affordable to be in 
regular follow up and may never have visited a local practitioner for minor illness.  Patients 
across all the socioeconomic strata presented with similar pre-hospital delays.  Thrombolysis 
was the preferred modality of reperfusion across all the socioeconomic groups.  Even though, 
this tertiary care centre was PCI capable and there was availability of experienced physicians 
and supporting staff, 24 hours a day, 7 days a week, only about 10% of the upper and middle 
class underwent primary PCI, while none among the lower class had primary PCI.  This is 
because of the prohibitive costs associated with PCI and lack of awareness among the lower 
class regarding the  benefits  of  PCI.   Compared to  Western  countries,  there  is  a  lack  of 
appropriate  use  of  insurance  cover  and  lack  of  health  program  initiatives  from  the 
government.  The use of coronary angiography was significantly restricted to only among the 
upper and middle class.  About 2/5th of the upper group underwent coronary angiography 
while less than 5% in the lower class had it done during the hospital  stay.   This practice 
pattern was similar to that reported by Xavier et al. in the CREATE registry.  There was no 
significant  difference across the groups with  regards to  pharmacotherapy.   Most  of  them 
received appropriate guideline based therapy and the use of guideline based acute medical 
therapy was much higher in comparison to that reported by Jose et al and Xavier et al.  We 
did not find any difference in mortality across the various socioeconomic groups.  There was 
no difference in the total duration of hospital stay either.  This was essentially because of the 
fact that patients across all  groups received appropriate guideline based therapy promptly 
without any disparity among the groups. CREATE registry had showed significant difference 
in treatment strategy among the different socioeconomic strata which ultimately reflected in 
the  greater  mortality  among  the  lower  socioeconomic  strata.   It  had  showed  that  the 
differences in mortality across socioeconomic strata in India are not due to differences in risk 
factors, but almost entirely to differences in treatments and related factors.  If all patients had 
access  to  similar  health  care  facilities,  reached  hospital  rapidly,  and  received  similar 
treatments, mortality would be reduced, especially for patients in the lower socioeconomic 
strata.  This was very much evident in present study as people across all the strata presented 
with similar time delays and received similar appropriate treatment and hence did not differ in 
mortality rates after STEMI.  This emphasizes the fact, that prompt recognition of symptom, 
rapid referral and initiation of treatment, making appropriate reperfusion therapy available at 
affordable cost, and implementing guideline based therapy with prescription of low cost but 
effective pharmacotherapy would definitely result in reduction in mortality and also bridge the 
gap between the socioeconomic strata.
Clinical and laboratory profile (Tables 8, 9, 10, 11)
The mean body mass index was 23 ± 6. The proportion of those who were overweight or 
obese was 35%.   This is similar to that seen in NRMI registry and CREATE registry. There 
was no significant difference among prevalence of overweight and obesity among males and 
females.  The  cut  off  for  body mass  index  differs  in  Asian  population,  where  the  risk  of 
cardiovascular disease starts occurring at a lower BMI cut off.  A cut off above 23.0  identifies 
people at higher risk for cardiovascular risk.  Applying this cut off, the proportion of overweight 
or obese increases to about 56%.
 More than 80% presented in Killips class I.  More males than females presented in Killips 
class I (P= 0.02).  Less than 10% presented in Killps class IV.  The mean ejection fraction 
was 45 ± 9%.  There was no significant difference in ejection fraction among males and 
females.  There was no significant difference in mean ejection fraction with respect to pre-
hospital delay.
An  equal  proportion  of  patients  with  presented  with  anterior  and  inferior  wall  myocardial 
infarction.  Extensive anterior wall MI was the most common location of MI.  Inferior wall MI 
was  more  often  associated  with  right  ventricular  myocardial  infarction  and  posterior  wall 
myocardial infarction.  Isolated inferior or lateral wall MI was not common.
The mean hemoglobin was significantly lower in women.  Troponin levels were significantly 
more among women.  This could be due to delayed presentation among women and hence 
greater time delay from onset of symptoms to collection of blood sample.   Serum creatinine 
was elevated in about 10%.  There was a trend towards higher mean triglyceride levels in 
women and lower mean HDL cholesterol levels in men.   The mean LDL cholesterol levels 
were higher and above the prescribed LDL goal of < 100mg/dl for patients with established 
cardiovascular disease.  About 5% were newly detected to have diabetes and about 70% 
were found to have LDL levels greater than 100mg/dl.
Management strategy (Tables 12, 13, 14  and Figure 2)
Thrombolysis was the most frequently used reperfusion strategy and streptokinase was the 
thrombolytic agent used in 95% of them.  Tenecteplase was used in the rest. Compared to 
the CREATE registry, greater proportion of patients received thrombolytic therapy (58.5% vs. 
86.7%).  Primary PTCA was utilized in this study only in 7% of patients.  This proportion is 
similar to that observed in the CREATE registry.  This is in sharp contrast to the Western 
data,  where the proportion undergoing thrombolysis  has fallen from 52.5% to 27.6% and 
proportion undergoing primary PCI has increased from 2.6% to 43.2% over the past 15 years. 
The  proportion  of  reperfusion  eligible  patients  who  did  undergo  any form  of  reperfusion 
therapy is very high in this study.  94% received either thrombolysis or primary PCI.  The 
management strategy in this study was primarily dependent on the financial affordability of 
patients.  The decreased use of  primary PCI  in  this  study is  due to  the  prohibitive  costs 
associated with  primary PCI in  comparison to thrombolytic  therapy,  inadequate insurance 
cover and lack of government health programmes to support such high end technologies. 
The numbers of PCI capable hospitals are very few and not all  of them offer services 24 
hours of the day.  Thrombolysis remains a cheap and effective option to primary PCI in India. 
It is widely available, easily administratable and can achieve results similar to primary PCI 
especially if initiated within 2 hours of symptom onset.  The crux of the issue is to reduce the 
pre-hospital and door-to-needle time for improving outcomes after thrombolysis.  In the NRMI 
2006 registry,  improvement in door-to-needle time has resulted in 16.5% adjusted relative 
improvement in mortality associated with thrombolytic therapy 128.  Thrombolysis remained the 
preferred treatment strategy across all groups of time delay, even after presenting later than 
12 hours from symptom onset.  Primary PCI was performed in all patients presenting with 12 
hours  of  pre-hospital  delay.   The proportion  of  patients  receiving  no  reperfusion  therapy 
increased with greater pre-hospital delay. None of the patients underwent emergency CABG.
ST-segment resolution post reperfusion is a simple clinical  marker of effective reperfusion 
therapy.  In  this  study,  about  60% of  patients  had  >50% ST  resolution  post  reperfusion 
therapy.  The proportion  of  patients  having  better  ST resolution  declined with  longer  pre-
hospital delay. Patients who presented within 12 hours had significantly better ST resolution. 
There was trend towards better ST segment resolution with primary PCI in comparison to 
thrombolysis.  Almost  90%  in  of  those  who  underwent  primary  PCI  achieved  >50%  ST 
resolution  compared  to  only  62%  among  thrombolysis.  But,  this  was  not  statistically 
significant, probably due to much reduced numbers undergoing primary PCI. 
Coronary angiography (Table 15)
Less than 2/5 of patients underwent coronary angiogram during index hospitalization. This 
compares well with CREATE registry, where about 22% underwent coronary angiography. 
The rate  of  coronary angiography is  far  less in  comparison to  Western countries,  where 
almost 80% undergo cardiac catheterization prior to discharge. Use of coronary angiography 
was largely restricted to upper and middle socioeconomic strata. There was no difference 
among males and females in undergoing coronary angiography. Among the patients, who 
underwent coronary angiography, PCI with stenting was done in 85% of patients.  PCI was 
not done in 3 of them due to severe triple vessel disease and one of the patients had a 
recanalised coronary artery.  60% had single vessel disease, while less than 15% had triple 
vessel disease.  Bare metal stent was implanted in 87% of those who underwent PCI.
Pharmacotherapy (Table 16, Figure 3)
There was tremendous improvement in prescription of guideline based acute medical therapy. 
Both aspirin and clopidogrel were used in almost 99% of patients.  Much greater improvement 
in prescription has been observed for beta-blockers, ACEI and statins.  Compared to Jose et 
al and CREATE registry where prescription of beta-blocker and ACEI were seen only in 60% 
of patients, almost 90% of them received these drugs in this study.  The largest gain has been 
observed for statins which was prescribed in nearly 94% of patients.  This rate is much higher 
than that shown in CREATE registry where statins were prescribed only in 50% of patients. 
The pattern of prescription of acute medications is well comparable with western data and in 
fact higher with respect to statins and ACEI 129.   This is due to greater awareness of evidence 
based treatments among the treating physicians and the wider use of internet for quick and 
complete access to the current and latest in field of cardiovascular medicine.  Less than a 
third of patients were prescribed anticoagulants.  Though ACC/AHA guidelines state class IA 
indication for routine use of anticoagulation post thrombolysis and for patients undergoing 
PCI,  use  of  anticoagulants  in  this  study was not  routinely prescribed in  all  patients  after 
thrombolysis and was limited to patients who were conservatively managed (received no form 
of reperfusion) or underwent PCI (primary /rescue or adjunct) and in those who had recurrent 
angina.   This  was  due  to  shorter  period  of  hospital  stay  in  uncomplicated  patients  and 
additional  financial  burden  associated  with  prescription  of  anticoagulants.  There  was  no 
observed difference in prescription pattern among males and females.
In-hospital complications and 30 day outcomes (Tables 17, 18, 19, 20, 21 and Figure 4)
In-hospital mortality observed was 12% which has declined from about 17% as observed by 
Jose et al,115  between the years 1999 – 2003.  This could be due to the greater improvement 
in the guideline based prescription of low cost but effective acute medical therapy, especially 
statins,  beta-blockers  and  ACEI.   Moreover,  greater  proportion  of  patients  received 
reperfusion therapy due to the reduction in pre-hospital  delay and achievement of shorter 
door-to-needle time.  Worldwide there has been a decline in in-hospital mortality from STEMI 
over the past 15 years.  The overall mortality in STEMI has reduced from 11.5 % to 8 % 4. 
Among patients undergoing thrombolysis, mortality has reduced from 7% in 1994 to 6% in 
2006.  Mortality among patients undergoing primary PCI has decreased from 8.6% in 1994 to 
3.1%  in  2006.   European  registries  show  a  greater  reduction  in  in-hospital  mortality116. 
Observed in-hospital mortality in STEMI in GRACE registry, declined from 8.4% in 1999 to 
4.6% in 2005 130.   In-hospital mortality observed in this study is higher in comparison to the 
Western data.  This may be due to the fact that primary PCI was utilized in fewer patients, 
with thrombolysis being the mainstay of therapy.  The greatest benefits of thrombolysis have 
been obtained in patients who present within 2 hours of symptom onset. There was greater 
observed pre-hospital  delay with only 20% of study population presenting within 2 hours, 
majority presenting only by 6 hours from symptom onset. There was greater prevalence of 
diabetes in this study group and higher incidence of mortality has been described in patients 
with diabetes who present with STEMI.  Invasive and intensive therapy could not be extended 
to all eligible patients due to financial constraints.  Moreover, this institution being a tertiary 
care centre,  there could be a referral  bias with  more high risk and sicker  patients  being 
referred from primary and secondary level hospitals.  Use of acute medications and timely 
reperfusion therapy (shorter door-to- needle and shorter door-to-balloon time) accounted for 
up to 21% of the relative reduction in annual mortality  129.    The other reasons stated for 
decline in mortality rates in western countries are improved public awareness campaigns, 
improvements in emergency medical services, more rapid triage of patients with chest pain 
syndromes in emergency departments, and geographic changes in hospital location128. 
The baseline characteristics of those who died in-hospital due to STEMI were similar for age, 
sex and risk factors, pre-hospital delay and type of reperfusion strategy used.  People who 
died had poor ECG ST-segment resolution compared to those who survived. (P=0.002).  The 
mean  ejection  fraction  was  also  significantly  lower  among  those  who  died  in-hospital. 
(P<0.002).   The degree of ST-segment resolution has been shown to be predictive of short-, 
medium, and long-term outcome131.   Heart failure and cardiogenic shock accounted for 60% 
of  the  in-hospital  mortality.   Fatal  arrhythmias  accounted  only  for  16%  of  the  deaths. 
Suspected myocardial rupture accounted for about 10% of the deaths.  All  the suspected 
ruptures occurred in those who received thrombolysis. Greater use of primary PCI could have 
reduced the deaths due to myocardial rupture. 
Apart  from LV systolic dysfunction, defined as ejection fraction less than 50% which was 
observed in about 2/3 of the study population, the other in-hospital outcomes were relatively 
uncommon. Re-infarction was less than 1% and stroke occurred in 1.3%.  Both the cases of 
stroke  were  observed  in  patients  who  received  thrombolysis.  The  proportion  of  those 
presenting with cardiogenic shock were much less (3.3%). Rescue PCI and adjunct PCI was 
done in 5.3% and 2.7% respectively.   The in-hospital  outcomes are comparable with the 
GRACE  registry.   Nearly  half  of  the  patients  had  an  uneventful  recovery  after  STEMI. 
Compared to that observed by Jose et al, all in-hospital outcomes occurred relatively less 
frequently.
The mean duration of hospital stay was shorter (2.6 ± 2 days.) The mean duration of hospital 
stay was similar across all the treatment groups. The observed duration of hospital stay is 
much shorter than that observed by Jose et al. (5.3 ± 3.4 days).
Most of the patients were free of outcomes at the 30 day follow up. Only 4 patients were lost 
to follow up. There was only one reported death. Heart failure and recurrent angina were 
observed equally among 12%.  The re-infarction rate was 2.7%. Compared to the Euro heart 
survey,  30 day mortality,  re-infarction rates are lower  but  heart  failure and recurrence of 
angina are higher.
Comparison between earlier study 115 and present study (Table 23)
The results of  the earlier  and present study are summarized in table 23. A total  of 1320 
patients diagnosed with STEMI were enrolled between 1999-2003. The mean age is similar in 
both the study. The proportion of women presenting with STEMI has increased. The mean 
pre-hospital delay has considerably shortened with more number of people presenting within 
6  hours.  The  prevalence  of  diabetes  has  increased,  while  smoking  has  become  less 
prevalent. The proportion of patients having past history of IHD has decreased.  Thrombolysis 
has remained the mainstay of reperfusion therapy.   The use of guideline based prescription 
has shown tremendous increase with most of the patients receiving acute medical therapy at 
rates comparable to the western registries. The in-hospital mortality rate has reduced, but still 
remains  higher  in  comparison  to  that  in  western  registries.  The  reduction  in  mortality  is 
explained by the shorter pre-hospital delay, increased use of guideline based therapy and due 
to  increased proportion  of  patients  undergoing  any form of  reperfusion  therapy.  There  is 
ample scope for further reduction in mortality by patient education and control of risk factors 
and increasing  the  awareness of  symptoms of  cardiovascular  disease,  reducing  the  pre-
hospital delay to increase the proportion of patients receiving reperfusion therapy, greater and 
judicious use of primary PCI at PCI capable centres and increase in the practice of use of 
guideline based therapies.
                              
LIMITATIONS
1. This is only an observational study and not a randomized control study. Hence, it cannot 
be used to compare outcomes among patient subsets.
2. The number of patients enrolled is very small and the time period of study was short and 
limited. Hence, the results are not generalizable.
3. The causes for time delay from onset of symptom to initial presentation to the physician 
have not been evaluated. Similarly, the causes for time delay at the local hospital for initial 
evaluation and subsequent transfer to tertiary care hospital have not been evaluated. 
4.  The mean hospital  stay was shorter in our study population due to early discharge of 
uncomplicated patients. It is likely that we might have missed a few mechanical complications 
like ventricular septal defect and papillary muscle rupture.
.
             
            
SUMMARY OF MAIN FINDINGS
1. The  mean  age  of  patients  presenting  with  STEMI  is  at  least  a  decade  younger  in 
comparison to Western populations.
2. The proportion of women presenting with STEMI has increased over the past decade.
3. Chest pain is the commonest symptom of presentation among both men and women, but 
it is reported at a significantly higher rate in men.
4. The  prevalence  of  diabetes  has  increased  and  women  have  significantly  higher 
prevalence of diabetics than men.
5. The mean pre-hospital delay is longer in comparison to Western populations.
6. The door-to-needle time is achieved more often if patients present directly to the chest 
pain unit of the tertiary care centre.
7. About half of the patients present with anterior wall MI and almost similar number present 
with inferior wall MI.
8. Most of the patients presenting with STEMI undergo reperfusion, and thrombolysis is the 
most commonly used reperfusion strategy.
9. Streptokinase is the most common thrombolytic agent used
10. Less than a third of patients undergo coronary angiography during index hospitalization.
11. Most of the patients are prescribed guideline based acute medical therapy and the use of 
these  therapies  is  higher  compared  a  decade  ago  and  is  similar  to  that  in  Western 
populations.
12. In-hospital mortality rates have declined compared to a decade ago but is higher  than in 
western populations.
13. Duration of hospital stay has shortened compared to that a decade ago.
14. Heart failure and recurrent angina are the most frequently reported adverse outcomes at 
30 day follow up.
15. There was no significant difference between the different socioeconomic strata with regard 
to reperfusion therapy, pharmacologic therapy, and in-hospital outcomes, but the lower 
socioeconomic group was less likely to undergo primary PCI or coronary angiography.
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STUDY PROFORMA
Pattern of presentation and management of STEMI in a tertiary care centre in a district 
capital in South India
 Name : Sl.No.





Occupation : Profession /   Semi-profession   / Clerical-Shop 
owner  –  Farmer  /  Skilled  worker/  Semi-skilled  worker  /   unskilled 
worker / Unemployed
Educational status: Professional or Honors / Graduate or Post graduate / 
 
 Intermediate or Post high school diploma / High school certificate Middle 
school certificate    / Primary School   / Illiterate
Income: > 13500    / 6750 – 13499    /   5050 – 6749    /   3373 – 5049 /      2025 – 
3374/ 676 – 2024   /    < 675
Date of admission : Date of Discharge :
Time from symptom onset to hospital :
Presentation to CPU   /   Accident and Emergency :
Referred by Primary level hospital/ secondary level hospital /    local practitioner   :
Symptoms: Chest pain     / Dyspnea       / palpitation / fatigue / syncope   / others
Risk Factors:  




Family history of IHD




Pulse Rate: BP:      mmHg RS: CVS :
Killips Class I / II / III   / IV
Other relevant system exam
ECG :
ECG ST resolution (post lysis):
Location of MI: ASMI Ext AWMI IWMI  
IWMI+RVMI  IW+RV+PWMI LWMI     LW + PWMI
ECHO: LVIDD/S:               EDV/ ESV: EF:         %;      MV E/A:     
DECT:    msec RWMA   :    MR: 
Blood inv: HB: TC /DC : AC/PC: Creatinine: 
Lipid profile:                           CKMB:         Troponin:
Reperfusion strategy:    Thrombolysis   /   Primary PTCA    / Conservative   
Door to needle time  : min
Agent used :   STK    / Urokinase / Tenecteplase
Primary PTCA :   SVD   / DVD   / TVD   / LM / Recanalised vessel
Door to balloon time :              min.
Stents used :   DES   / BMS
Other therapy :   Aspirin   /  Clopidogrel  /  ACEI  /  Beta blockers   / Statins  / 
ARB   /  Nitrate /   Diuretics /  TPI
Anticoagulant therapy :  Heparin   / LMWH / Fondaparinux
In-hospital outcomes :  Death   / Re-infarction   / Recurrent angina   / Arrhythmias / LV 
systolic   dysfunction/ Stroke / Bleeding / Cardiogenic shock / Pericarditis /   Rescue PCI   / 
adjunct PCI/  VSR     /   MR     / Complete heart block / Uneventful   / Others
CAG in index admission :  Yes   / No
Duration of hosp. stay :
30 day outcome :   Death / Re-infarction / Heart failure / Arrhythmia / Recurrent angina / 
Stroke/    Uneventful / Others
                                   
GLOSSARY
CVD - Cardiovascular disease
STEMI - ST-segment elevation myocardial infarction
PCI - Percutaneous coronary intervention
ACEI - Angiotensin converting enzyme inhibitors
AMI - Acute myocardial infarction
PAR - Population attributable risk
IHD - Ischaemic heart disease
ACS - Acute coronary syndrome
AWMI - Anterior wall myocardial infarction
ASMI - Antero septal myocardial infarction
IWMI - Inferior wall myocardial infarction
LWMI` - Lateral wall myocardial infarction
PWMI - Posterior wall myocardial infarction
A&E - Accident & Emergency unit 
CPU - Chest pain unit
Master chart 
Hospno - Hospital number
SES - Socioeconomic status (1-upper, 2-upper middle, 3-lower 
middle, 4-upper lower, 5-lower)
TIMED1 - Time to first medical contact in minutes
TIMED2 - Window period in minutes
TIMED3 - Door-to-needle time
TIMED4 - Door-to-balloon time
TIMED5 - Transfer delay from accident and emergency unit to 
chest pain unit
TIMED6 - Delay to transfer from first medical contact to tertiary 
care centre
TIMED7 - Pre-hospital delay in minutes
PLACEFIR - Place of first medical contact (1-local hospital, 2- A&E, 
3-CPU)
CHESTPAI - Chest pain (1-yes, 2-no)
PALPITAT - Palpitation (1-yes, 2-no)
RFDIABET - diabetes mellitus (1-yes, 2-no)
HYPERTEN - Hypertension (1-yes, 2-no)
FAMILYHI - Family history of coronary artery disease (1-yes, 2-no)
PASTIHD - Past history of ischaemic heart disease (1-yes, 2-no)
DYSLIP - Dyslipidemia (1-yes, 2-no)
POSTMEN - Postmenopausal (1-yes, 2-no)
NONE - No risk factor (1-yes, 2-no)
BMI - Body mass index 
PR - Pulse rate
BPS - Systolic blood pressure
BPD - Diastolic blood pressure
ECGSTRES - ECG ST resolution (1-<50, 2->50)
LOCATION - Location of infarct (1 - ASMI, 2 - Ext AWMI, 3 - IWMI, 
4–IWMI+RVMI, 5–IWMI+RVMI+ PWMI,                            
6   -   IWMI  +RVMI+PWMI+LWMI,  7-LWMI,  8-
LWMI+PWMI)
EF - Ejection fraction 
CREAT - Creatinine 
TROPO - Troponin I
TCH - Total cholesterol
TG - Triglyceride
HDL - High density lipoprotein
LDL - Low density lipoprotein
DMNE - Newly detected diabetes (1-yes, 2-no)
DYSLIPI - Newly detected Dyslipidemia (1-yes, 2-no)
REPERFS - Reperfusion strategy (1-thrombolysis, 2-primary PCI, 3-
conservative)
THROMBO - Thrombolytic agent used (1-streptokinase, 2-urokinase, 
3-tenekteplase)
PRIMA - Coronary artery disease (1-single vessel disease, 2-
double vessel disease, 3-triple vessel disease, 4-recanalised vessel)
CAGINDEX - Coronary angiogram in index hospitalization (1-yes, 2-no)
ASPIRIN - Aspirin (1-yes, 2-no)
CLOPID - Clopidogrel  (1-yes, 2-no)
ACEI - ACEI (1-yes, 2-no)
BETABLOC - Beta-blockers (1-yes, 2-no)
ARB - Angiotensin receptor blockers (1-yes, 2-no)
TPI - Temporary pacemaker insertion (1-yes, 2-no)
DIG - Digoxin (1-yes, 2-no)
DIURETI - Diuretics (1-yes, 2-no)
NITRATE - Nitrates (1-yes, 2-no)
STATINS - Statins (1-yes, 2-no)
ANTICOAG - Anticoagulant  agent  used  (1-heparin,  2-lmwh,  3-
fondaparinux, 4-none)
INHOSPIT – In-hospital mortality (1-yes, 2-no)
REINFARC – Reinfarction (1-yes, 2-no)
RECURREN - Recurrent angina (1-yes, 2-no)
ARRYTHMI – Arrhythmia (1-yes, 2-no)
LVDYSFN - LV systolic dysfunction (EF < 50%) (1-yes, 2-no)
PERICARD - Pericarditis (1-yes, 2-no)
RESCUEPC - Rescue PCI (1-yes, 2-no)
VSR - Ventricular septal rupture (1-yes, 2-no)
MR - Mitral regurgitation (1-yes, 2-no)
CHB - Complete heart block (1-yes, 2-no)
UNEVENT - Uneventful in-hospital stay (1-yes, 2-no)
ADJUNCT - Adjunct PCI (1-yes, 2-no)
DOHSTAY – Duration of hospital stay 
THDDEATH - Mortality at 30 day follow up (1-yes, 2-no)
REINFAR – Reinfarction at 30 day follow up (1-yes, 2-no)
ARRHYT - Arrhythmia at 30 day follow up (1-yes, 2-no)
REANGINA - Recurrent angina at 30 day follow up (1-yes, 2-no)
HEARTFAI - Heartfailure at 30 day follow up (1-yes, 2-no)
STROKET - Stroke at 30 day follow up (1-yes, 2-no)
UNEVENTF - Uneventful at 30 day follow up (1-yes, 2-no)

